
==== Front
Cell Mol Biol Lett
Cell Mol Biol Lett
Cellular & Molecular Biology Letters
1425-8153
1689-1392
BioMed Central London

39237893
633
10.1186/s11658-024-00633-2
Mini Review
Lysosome quality control in health and neurodegenerative diseases
Ferrari Veronica 1
Tedesco Barbara 1
Cozzi Marta 1
Chierichetti Marta 1
Casarotto Elena 1
Pramaggiore Paola 1
Cornaggia Laura 1
Mohamed Ali 1
Patelli Guglielmo 2
Piccolella Margherita 1
Cristofani Riccardo 1
Crippa Valeria 1
Galbiati Mariarita 1
http://orcid.org/0000-0002-8883-0468
Poletti Angelo angelo.poletti@unimi.it

1
Rusmini Paola 1
1 https://ror.org/00wjc7c48 grid.4708.b 0000 0004 1757 2822 Dipartimento di Scienze Farmacologiche e Biomolecolari “Rodolfo Paoletti”, Università degli Studi di Milano, Dipartimento Di Eccellenza, 2018-2027 Milan, Italy
2 https://ror.org/05rbx8m02 grid.417894.7 0000 0001 0707 5492 Unit of Medical Genetics and Neurogenetics, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy
5 9 2024
5 9 2024
2024
29 11612 4 2024
13 8 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by/4.0/ Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Lysosomes are acidic organelles involved in crucial intracellular functions, including the degradation of organelles and protein, membrane repair, phagocytosis, endocytosis, and nutrient sensing. Given these key roles of lysosomes, maintaining their homeostasis is essential for cell viability. Thus, to preserve lysosome integrity and functionality, cells have developed a complex intracellular system, called lysosome quality control (LQC). Several stressors may affect the integrity of lysosomes, causing Lysosomal membrane permeabilization (LMP), in which membrane rupture results in the leakage of luminal hydrolase enzymes into the cytosol. After sensing the damage, LQC either activates lysosome repair, or induces the degradation of the ruptured lysosomes through autophagy. In addition, LQC stimulates the de novo biogenesis of functional lysosomes and lysosome exocytosis. Alterations in LQC give rise to deleterious consequences for cellular homeostasis. Specifically, the persistence of impaired lysosomes or the malfunctioning of lysosomal processes leads to cellular toxicity and death, thereby contributing to the pathogenesis of different disorders, including neurodegenerative diseases (NDs). Recently, several pieces of evidence have underlined the importance of the role of lysosomes in NDs. In this review, we describe the elements of the LQC system, how they cooperate to maintain lysosome homeostasis, and their implication in the pathogenesis of different NDs.

Graphical Abstract

Keywords

Lysosome
Galectins
Neurodegeneration
Lysosomal membrane permeabilization
Lysosome quality control
Università degli Stuti di Milanopiano di sviluppo della ricerca (PSR) UNIMI Ferrari Veronica http://dx.doi.org/10.13039/501100002426 Fondazione Telethon GGP19128 Poletti Angelo Fondazione Cariplo2021-1544 Cristofani Riccardo http://dx.doi.org/10.13039/501100007802 Fondazione Italiana di Ricerca per la Sclerosi Laterale Amiotrofica MLOpathy Target-RAN Poletti Angelo http://dx.doi.org/10.13039/501100004923 AFM-Téléthon 23236 Poletti Angelo http://dx.doi.org/10.13039/100003914 Kennedy's Disease Association 2018 grant 2020 grant Cristofani Riccardo Galbiati Mariarita http://dx.doi.org/10.13039/501100021856 Ministero dell'Università e della Ricerca PRIN n. 2017F2A2C5 PRIN n. 2022EFLFL8 PRIN n. 2020PBS5MJ PRIN n. 2022KSJZF5 PRIN n. P2022B5J32 PRIN n. P20225R4Y5 CN3: RNA – Codice Proposta: CN_00000041 Progetto Dipartimenti di Eccellenza to DiSFeB Cristofani Riccardo Crippa Valeria Poletti Angelo http://dx.doi.org/10.13039/501100003197 Agenzia Italiana del Farmaco, Ministero della Salute Co_ALS Poletti Angelo http://dx.doi.org/10.13039/100012352 Università degli Studi di Milano piano di sviluppo della ricerca (PSR) UNIMI piano di sviluppo della ricerca (PSR) UNIMI Tedesco Barbara Cristofani Riccardo issue-copyright-statement© University of Wroclav 2024
==== Body
pmcLysosomal functions

Lysosomes are membrane-enclosed acidic organelles found in all eukaryotic cells, discovered by De Duve in the middle of the last century [1, 2]. Lysosomes contain a wide range of hydrolases capable of degrading all macromolecules present in cells: nucleic acids, lipids, carbohydrates, proteins, and cell debris. For decades lysosomes have been considered the “trash bin” of cells, without any other specific role [3]. In the last 10 years, however, research on lysosomal function has intensively increased and nowadays these organelles are considered an important hub for cell metabolism and nutrient sensing [4, 5]. Lysosomal functions are involved in: endocytosis, phagocytosis, autophagy [6], lysosome exocytosis and plasma membrane repair [7, 8], control of nutrient sensing [9, 10], and cell death processes [11]. This variety of functions implicates lysosomes in many human diseases. Notably, defects in genes coding for lysosomal enzymes are causative factors in a group of more than 50 inherited metabolic disorders. These disorders, named lysosomal storage disorders (LSDs), are characterized by the lysosomal accumulation of undigested substrates, and include Gaucher disease, Fabry disease, and Neimann–Pick disease [12–14]. Lysosomal dysfunctions have been also found to play important roles in cancer [15, 16] and neurodegenerative diseases (NDs) [17–24]. In most cases, these diseases show adulthood onset and a progressive decline. In addition, the decrease in lysosomal function observed during ageing may contribute to disease pathogenesis [25].

Lysosomal membrane composition

Extracellular material, intracellular molecules, and organelles are driven to lysosomes for degradation. Lysosomal catabolic functions require that these components are transported and delivered to the lumen of the organelle, where the acidic hydrolytic enzymes degrade the substrates. The integrity of the limiting membrane is crucial for the proper functionality of lysosomes, and this is ensured by a thick membrane (around 8 nm) composed of lipids and glycoproteins with a luminal glycosylated domain [26]. This lysosomal glycocalyx has a protective role in the acidic environment, and it is fundamental for the functionality of the lysosomal membrane proteins [i.e., lysosomal integral membrane proteins (LIMPs) and lysosomal associated membrane proteins (LAMPs)]. Alongside soluble lysosomal hydrolases, lysosomal membrane proteins play a pivotal role in organelle biogenesis and functionality [27, 28]. Among these, LAMP-1, LAMP-2, LIMP-1/CD63 and LIMP-2/SCARB2 are the most abundant, with the former two representing more than 50% of total lysosomal membrane proteins [29]. Since their discovery, LAMP-1 and LAMP-2 have been considered structural molecules committed to ensuring lysosome integrity by protecting the membrane from the acidic luminal compartment [30]. Recently, it has been demonstrated that these proteins perform functions beyond this preservation and that, despite their 37% sequence homology, they show important functional differences from one another. Experiments performed in mice show that the inactivation of the Lamp1 gene does not alter lysosomal morphology and function [31], while in Lamp2-deficient mice, increased cell mortality correlating with the accumulation of autophagic vacuoles (AVs) occurred in several tissues [32]. Lamp2-deficient mice model the symptoms of Danon disease in humans, an LSD caused by Lamp2 mutations characterized by abnormal accumulation of AVs in heart and in skeletal muscle [33, 34].

Another factor that contributes to the stability of the lysosomal membrane is lipid composition. Lysosomal membranes are enriched in sphingomyelin and are characterized by the presence of bis(monoacylglycerol)phosphate, a negatively charged lipid exclusively present in lysosomes [35–37]. Of note, cholesterol is an essential heterogeneously distributed membrane component, mainly present in the plasma membrane [38]; however, the lysosome represents a unique organelle in terms of cholesterol content, since its membrane cholesterol composition is intermediate between that of the plasma membrane and that of other intracellular organelles [39]. Indeed, lysosomes play a key role in maintaining cholesterol homeostasis and in cholesterol dynamics [39–41]. Thus, alterations in the cholesterol content affect the integrity and stability of the lysosomal membrane and a reduction in its levels induces lysosomal membrane permeabilization (LMP; see below for a detailed description) [42]. Conversely, the addition of cholesterol to isolated lysosomes or cell cultures increases lysosomal membrane stabilization [43–45].

Lysosomal quality control

Given the central role of lysosomes for cellular homeostasis, any stress or alteration that affects lysosomal integrity can critically impact cell viability. To maintain lysosomal functionality, lysosomal damage is recognized and resolved by lysosomal quality control (LQC). The LQC consists of multiple pathways dedicated to lysosomal repair, clearance (lysophagy), exocytosis, and biogenesis. LQC is generally activated in response to LMP, an event characterized by membrane damage, lysosomal swelling, and the release of lysosomal luminal content into the cytosol with possible uncontrolled breakdown of biomolecules [46, 47]. In addition to the previously mentioned changes in cholesterol content in the lysosomal membrane, a variety of exogenous and endogenous factors can cause LMP, including lysosomotropic agents, compounds entrapped in the lysosomes after protonation (l-leucyl-l-leucine methyl ester hydrobromide, glycyl-l-phenylalanine 2-naphthylamide, chloroquine, and the cationic amphiphilic drugs), reactive oxygen species, the apoptotic regulator Bcl-2-like protein 4, and infectious pathogens [48, 49]. LMP may also occur in response to neurotoxic events in NDs (see Lysosomal Damage in Neurodegeneration section for details) [50–56].

Lysosomal damage recognition and repair

To cope with lysosomal damage, cells have sensor proteins capable of recognizing lysosomal damage and activating intracellular responses (Fig. 1). These proteins are the galectins, a group of 15 proteins characterized by the presence of a common carbohydrate recognition domain, a beta-sandwich domain composed of 130–140 residues with high affinity for carbohydrates [57].Fig. 1 Lysosome repair. Lysosomal membrane permeabilization (LMP) and damage is recognized and repaired by mechanisms such as the PITT, the ESCRT pathways, and the sphingomyelin scrambling and turnover. (i) The PITT mechanisms consist of protein complexes that promote lysosome lipid membrane turnover by interacting with endoplasmic reticulum (ER). (ii) The ESCRT machinery is recruited by galectins and restores lysosome membrane integrity. (iii) The remodeling of damaged lysosomal membrane can be directed by sphingomyelin scrambling and turnover. Created with BioRender.com

Galectins are small, soluble, and dynamic cytosolic proteins, that can shuttle into the nucleus or be secreted into the extracellular environment by unconventional secretion processes [58, 59]. Multiple pathways seem to be implicated in galectin secretion; evidence suggests it can be mediated by direct release, by lysosome/endosome exocytosis, or by extracellular vesicle release [59]. In the extracellular space, secreted galectins may bind to specific beta-galactosides forming a cross-linked complex, a dynamic lattice [60], and play important roles in cell adhesion, cell migration, signaling, immune response, inflammation, and endocytosis [61–64]. At the intracellular level, galectins reside in the cytosol, but, when necessary, they can recognize and bind to damaged endosomal membranes [65, 66], with galectins-3, 8, and 9 being mostly involved. In normal conditions, glyco-conjugates are present in the lumen of lysosomes and endosomes, but upon membrane disruptions, they are exposed to the cytosol and may be recognized by galectins. Indeed, the accumulation of galectins in discrete cytosolic puncta is a hallmark of LMP [67]. In the presence of a small rupture in the lysosomal membrane, galectin-3 translocates to the lysosomes and recruits the programmed cell death 6 interacting protein (PDCD6IP/ALIX), tumor susceptibility 101 (TSG101), the Endosomal sorting complex required for transport III (ESCRT-III) component charged multivesicular body protein 4B (CHMP4B), and VPS4 essential proteins for lysosomal membrane repair [66, 68–70]. This process is followed by lysosomal calcium efflux and triggers the RAB29-mediated translocation of the leucine-rich repeat kinase 2 (LRRK2) to the damaged lysosomes. LRRK2 phosphorylates and engages RAB8A facilitating the recruitment of ESCRT components for membrane repair [17, 71, 72]. Concurrently, LRRK2 also recruits and activates both RAB10 and its protein interactor C-Jun-amino-terminal kinase-Interacting Protein 4 (JIP-4) promoting the lysosomal tubulation sorting, a process driven by LRRK2 and necessary for the release of vesicles from lysosomes [73, 74].

Evidence showing that ESCRT depletion was not fully capable counteracting lysosomal repair suggests that this is not the only lysosomal repair mechanism [68, 70].

Recently, two ESCRT-independent pathways for lysosomal membrane repair have been discovered.

Tan and Finkel identified phosphoinositide-initiated membrane tethering and lipid transport (PITT), a specific set of proteins involved in LMP beyond the known ESCRT components including the membrane-bound phosphatidyl-inositol-4 kinase type 2 alpha (PI4K2A) [75, 76]. This enzyme catalyzes the phosphorylation of phosphatidyl-inositol (PI) to phosphatidyl-inositol 4-phosphate (PI4P), a lipid essential for the endolysosome system, as well as its binding proteins, the oxysterol binding protein (OSBP) related 9, 10, and 11 (ORP9, ORP10 and ORP11). In this alternative repair pathway, LMP induces the activity of PI4K2A leading to the production of PI4P and the lysosomal accumulation of ORP9, ORP10, and ORP11; these are subsequently involved in the formation of inter-organelle membrane contact sites (MCS). ORP proteins dimerize with each other and establish endoplasmic reticulum (ER)-lysosome MCS via the interaction of the ER-resident VAMP-associated proteins A and B, favoring the exchange of PI4P with phosphatidyl-serine (PS) and transporting it to lysosomes. In a complementary way, OSBP transports cholesterol to damaged lysosomes for repair. The accumulation of PS in lysosomes stimulates the non-canonical activity of the autophagy-related 2 (ATG2) protein, involved in lipid transport [76]. The link between the ESCRT-pathway and PITT in lysosomal membrane repair remains to be elucidated.

The second ESCRT-independent mechanism for lysosomal repair has been uncovered by Niekamp and colleagues. The process is triggered by cytosolic exposure of sphingomyelin to the surface of damaged lysosomes catalyzed by the Ca2+-dependent scramblase. This is followed by the cleavage of sphingomyelin by neutral sphingomyelinase to produce ceramides facilitating membrane repair [77]. These repair pathways act in parallel to ensure lysosome integrity.

Interestingly, it has been shown that lysosomal damage inactivates mTOR, which normally functions to negatively regulate autophagy and catabolic pathways. This is mediated through a galectin-based system named GALTOR, suggesting a link between lysosomal damage and the regulation of cellular metabolism [78].The system is based on the interaction between galectin-8, the lysosomal aminoacidic transporter solute carrier family 38 member 9,and the ragulator–Rag complex. Concurrently, galectin-9 activates AMP-activated protein kinase (AMPK) increasing its phosphorylating activity via association with the AMPK upstream kinase mitogen-activated protein kinase 7 (MAP3K7/TAK1). The interaction between galectin-9 and the deubiquitinase ubiquitin-specific peptidase 9 X linked (USP9X) governs the lysine 63 ubiquitination (K63) rate of MAP3K7/TAK1, a process that regulates and activates the enzyme. In physiological conditions, USP9X negatively regulates MAP3K7/TAK1 activity by deubiquitination; instead, under LMP conditions, galectin-9 interferes with USP9X promoting MAP3K7/TAK1 ubiquitination and activation [66, 79].

Lysophagy

When the lysosomal membrane cannot be repaired, a complex mechanism is activated to promote the clearance of the whole organelle via selective autophagy, a process known as lysophagy (Fig. 2). Lysophagy is activated when repair mechanisms fail. To date, the exact mechanism responsible for the switch from lysosomal repair to clearance has not been characterized. Indeed, the degradation of damaged lysosomes is mainly triggered by the recruitment of galectins; galectins sense the LMP, bind exposed glycans, and recruit enzymes involved in lysosome ubiquitination (E2, E3 enzymes); these processes mainly involve galectin-3 and galectin-8. Galectin-3 recruits and binds the tripartite motif-containing 16 (TRIM16), an atypical E3 ubiquitin ligase that contributes to lysosome ubiquitination and serves as a platform to recruit autophagy-related proteins such as ULK1, ATG16L, and BECN-1 [52, 80]. These proteins are all part of complexes that together regulate autophagy initiation by mediating the formation of the phagophore, a double-membraned structure, and the activation of microtubule-associated protein 1 light chain 3 (MAP1LC3, or simply LC3). Thus, TRIM16 mediates the interaction between lysosomes and the forming phagophore, facilitating the engulfment of the damaged lysosomes. Moreover, TRIM16 regulates the activation of the transcription factor EB (TFEB), the master regulator of autophagy and lysosome biogenesis (see below for a detailed description) [80]. In parallel to galectin-3, galectin-8 directly binds a specific autophagy receptor (AR), the calcium-binding and coiled-coil domain 2 protein (CALCOCO2, also known as NDP52). NDP52 recruits the forming phagophore and interacts with the ragulator–Rag complex inhibiting mTOR and therefore activating TFEB [66]. Hence, TFEB activation induces the transcription of autophagic genes responsible for lysophagy and lysosomal biogenesis (see below for a detailed description of TFEB activity).Fig. 2 Lysophagy. Lysosome clearance through autophagy is activated when the repair mechanisms fail or the damage persists. Lysosome clearance can occur by marking the damaged lysosomes and recruiting them to the forming phagophore via various galectin-dependent or independent mechanisms. Created with BioRender.com

Ubiquitination of damaged lysosomes is also regulated through galectin-independent mechanisms by E2 and E3 enzymes, such as the SKP1/CUL1/F-box (SCF) protein ubiquitin ligase complex, Cullin-4A—DNA damage-binding protein—WD repeat and FYVE domain-containing 1 complex, and UBE2QL1. Ubiquitination can occur on K63- or K48- linked ubiquitin chains. ARs recognize K63-linked ubiquitin conjugates, while K48-linked chains generally are associated with proteasome degradation. K63- and K48-ubiquitinations on lysosomal membrane proteins occur with a different timing and play different roles. K63-ubiquitination arises quickly after the damage, together with the recruitment of the AR sequestosome-1 (SQSTM1/p62). Different ligases can mediate K63 ubiquitination: F-box protein 27, the substrate recognition subunit of the SCF complex, directly binds to glycans and damaged lysosome membranes promoting LAMP-1 and LAMP-2 K63 ubiquitination; ITCH ubiquitylates membrane-associated proteins to initiate lysophagy. ITCH is recruited and activated by SPART/SPG20, a galectin/LMP-independent detector of lipid-packing defects on the lysosome membrane. SPART/SPG20 binds to IST1, a repair factor, and senses membrane defects that precede LMP. When lipid membrane alterations are unacceptable, SPART/SPG20 recruits ITCH initiating autophagy [81, 82].

K48-ubiquitination occurs later on and is mediated by E2 or E3 enzymes such as UBE2QL1 or Cullin-4A [83–85]. The K48 conjugates targeted by UBE2QL1 are recognized by the heat shock protein B1 (HSPB1), which favors their segregation by valosin-containing protein (VCP) and their clearance by the proteasome [86, 87]. The first set of proteins targeted by ubiquitination is ARs, which promote phagophore engulfment [81]. Subsequently, the second set of ubiquitinated proteins is membrane trafficking regulators, such as soluble n-ethylmaleimide-sensitive factor attachment protein receptors, which suppress the fusion of damaged lysosomes with autophagosomes or late endosomes. Finally, the third set of proteins targeted by ubiquitination are proteins that orchestrate the cytoskeleton in lysophagy dynamics, such as cellular communication network factor 2. The clearance of this last set of proteins is regulated by VCP and is necessary for lysosomal degradation [86].

Damaged lysosomes, marked with ubiquitin-chains, are linked to autophagic membranes by ARs [e.g.: SQSTM1/p62, optineurin (OPTN), NDP52, NBR1 autophagy cargo receptor (NBR1), Tax1 binding protein 1]. They possess an ubiquitin-associated domain, which recognizes ubiquitin chains, and an LC3-interacting region, which directly binds LC3 present on the forming phagophore. AR activation is regulated by TANK-binding kinase 1 (TBK1), which by phosphorylating them, increases their affinity to ubiquitin chains [88, 89]. SQSTM1/p62 is the major actor in lysophagy; in fact, it is consistently found on damaged lysosomes and its depletion prevents lysosome clearance [81, 83, 90]. The recruitment of SQSTM1/p62 upon lysosomal damage is regulated by HSPB1. During phagophore formation, HSPB1 is recruited to lysosomes and is phosphorylated to allow its inclusion in the SQSTM1/p62 condensates (also known as p62 bodies) formed by liquid–liquid phase separation (LLPS), favoring the maintenance of its liquid–liquid phase properties, and thus promoting lysophagy [90].

Besides the canonical pathway just described, lysosomal damage also induces non-canonical lysophagy. In this process, the ATG12/ATG5/ATG16 complex is recruited to the lysosomal membrane through a V-ATPase-mediated process. Consequently, activated LC3 is directly attached to the lysosomal membrane by non-canonical autophagy and conjugation of ATG8s to single membranes (CASM). This is likely followed by (i) recruitment of the lipid transfer protein ATG2, which is involved in PITT-dependent lysosome repair, and (ii) the fusion of LC3-labeled vesicles with other intact lysosomes [91–93].

Lysosomal biogenesis and exocytosis

Lysosomal biogenesis and replacement are adaptive mechanisms that maintain the functional pool of lysosomes needed for cellular homeostasis (Fig. 3). These processes depend both on the endocytic pathway and on the biosynthesis of new lysosomal proteins; they further require the coordinated transcription of genes coding for lysosomal and autophagic proteins regulated by TFEB and by its cognate transcription factor E3 (TFE3). These two proteins belong to the microphthalmia (MiT/TFE) family of basic helix-loop-helix-leucin zipper transcription factors, a class of evolutionarily conserved and structurally related proteins. This family includes four members: the microphthalmia transcription factor, TFEB, TFE3, and the transcription factor EC. TFEB and TFE3 recognize a 10 bp palindromic responsive element (GTCACGTGAC), termed the coordinated lysosomal expression and regulation, present in genes controlling the integrated expression of networks regulating autophagy and lysosomal biogenesis, exocytosis [94–97].Fig. 3 Lysosome biogenesis and exocytosis. To maintain the pool of functional lysosomes the damage of lysosomes activates galectin-dependent mechanisms that induce the transcription factors TFEB and TFE3. Exocytosis of damaged lysosomes with a Ca2+-dependent process is induced as an alternative mechanism to lysophagy. Created with BioRender.com

TFEB and TFE3 continuously shuttle between cytosol and nucleus, and different stimuli can modify the dynamics of this mechanism. When sufficient nutrients are available, the mTOR complex 1 (mTORC1) inhibits TFEB/TFE3 activity through their phosphorylation (at Ser138, Ser142, or Ser211 for TFEB; at Ser321 for TFE3) [98]. Conversely, starvation or cellular stress conditions promote TFEB activation and nuclear translocation with two parallel mechanisms: by switching off mTORC1 activity and by inducing lysosomal calcium efflux via the mucolipin TRP cation channel 1 (MCOLN1), an event that triggers the activation of the calcium-dependent serine/threonine phosphatase calcineurin that dephosphorylates TFEB/TFE3, thus activating them. [94, 99]. The mitogen-activated protein kinase 1 (MAPK1/ERK2) and the protein kinase C type beta are also involved in TFEB phosphorylation and regulation [100].

How TFEB/TFE3 phosphorylation inhibits their function has been elucidated. Specific phosphorylated serine residues allow both the recognition and the binding of the chaperone YWHA/14-3-3 that retains TFEB/TFE3 in the cytosol [101–104] and mediates their nuclear export via exportin1 (known as chromosomal maintenance 1) [105, 106], thus preventing their nuclear localization.

Beyond phosphorylation, other post-translational modifications control TFEB/TFE3 activity, including acetylation, a process regulated by histone deacetylases (HDAC2, HDAC5, HDAC6, HDAC9) and acetyltransferases (ACAT1, ELP3, CREBP). Treatment with pan-HDAC inhibitors, such as suberoylanilide hydroxamic acid or trichostatin, induces TFEB acetylation and accumulation into the nucleus, promoting lysosomal biogenesis and autophagy [107, 108]. Finally, TFEB/TFE3 are also involved in the redox signaling mediated by the KEAP1/NRF2 pathway, suggesting that lysosomal biogenesis might also be sensitive to the intracellular redox state [109].

In the nucleus, both TFEB and TFE3 exert their transcriptional activity through an LLPS-dependent mechanism involving the formation of physiological protein condensates, which also regulate their activity. It has been demonstrated that the inositol polyphosphate multikinase (IPMK) does not influence TFEB phosphorylation or nuclear translocation, but IPMK can associate with TFEB suppressing its LLPS. IPMK knockdown induces the formation of TFEB condensates promoting its transcriptional activity and leading to autophagy induction and lysosomal biogenesis [110, 111].

Lysosomal damage and LMP have been shown to induce TFEB activation and lysosomal biogenesis to replace the pool of damaged lysosomes cleared by lysophagy [112, 113]. Besides the role of galectin-8 described above, other proteins might be involved in the activation of TFEB following LMP. In kidney injury, it has been observed that lysosomal damage triggers the recruitment of LC3 by the activation of ATG conjugation system. LC3 interacts with MCOLN1 leading to calcium efflux, which induces TFEB nuclear translocation through the activation of calcineurin [114]. Interestingly, it has been recently observed that calcineurin is also indirectly regulated by galectin-3: galectin-3 recruits the SMAD specific E3 ubiquitin-protein ligase SMURF1 to damaged lysosomes, which in turn binds and controls calcineurin promoting its phosphatase activity on TFEB [115].

A peculiar activity of TFEB is its involvement in the regulation of lysosome exocytosis; this process requires that lysosomes fuse directly with the plasma membrane to release their content into the extracellular environment. Lysosomal exocytosis was shown to be involved in the restoration or remodeling of the plasma membrane [116–119], as well as in neurite outgrowth processes and axonal myelinization [120–122].

Lysosomal exocytosis is regulated by lysosomal calcium efflux through the MCOLN1 channel. Interestingly, TFEB overexpression stimulates the activation of MCOLN1 and calcium release from lysosomes mediating lysosomal exocytosis. TFEB and MCOLN1 act in a feedback loop, where TFEB triggers MCOLN1 gene transcription, being a TFEB target gene, while MCOLN1 stimulates TFEB activation via calcineurin, as described above [95].

Recent findings suggest lysosomal exocytosis as a mechanism for the secretion of protein aggregates from neurons, contributing to the maintenance of cellular proteostasis when intracellular degradative systems are impaired [123].

Lysosome reformation

Beside lysosomal biogenesis, cells can provide a new pool of lysosomes via reformation processes. Lysosomes can also originate through the recycling of the autolysosome membrane via a mechanism known as autophagic lysosome reformation (ALR). ALR involves the protrusion of tubules from autolysosomes, giving rise to small vesicles named proto-lysosomes, which subsequently mature into functional lysosomes [124]. The initiation of ALR is dependent on the reactivation of mTOR. The mechanisms governing mTOR reactivation and the subsequent initiation of ALR during autophagy are still mostly unclear. An important process implicated in this context is the increased production of amino acids, which activates mTOR [124]. Moreover, the release of calcium by lysosomes also plays a role in mTOR activation through a calmodulin-dependent mechanism [125].

The remodeling of autolysosome membranes during ALR is finely regulated by the transient and reversible formation of a specific set of membrane-bound phosphoinositides, following a precise spatiotemporal pattern. Notably, PtdIns P2 recruits clathrin to the autolysosome membrane, which, in turn, stimulates membrane budding [126]. Clathrin additionally serves as a membrane platform to facilitate the accumulation of AP-2-PtdIns P2, which, in turn, promotes the recruitment and clustering of the kinesin family member 5B (KIF5B) protein. KIF5B is a kinesin motor protein that binds to autolysosome membranes and microtubule filaments, thereby facilitating the formation of autolysosome membrane tubules. Finally, the mechanism that promotes the final scission of the lysosome is still unclear [127]. Interestingly, it has been recently demonstrated that, in the presence of severe LMP, the ALR machinery is recruited to damaged lysosomes by TBC1 domain family member 15 to regenerate functional lysosomal membranes. This mechanism represents a prompt cellular response to compensate for the reduction of functional lysosomes before the activation of lysosomal biogenesis mediated by TFEB/TFE3 [128].

Alternatively, lysosomes are also regenerated by the endocytic pathway. Transient “kiss and run” interactions between late endosomes and lysosomes occur to deliver the endocytosed cargoes into the lysosomes. These events result in the formation of endolysosomes, hybrid and heterogeneous organelles from which lysosomes are regenerated with an analogous pathway to that occurring in ALR: characterized by tubulation of endolysosomes, scission, and maturation [129–133].

Lysosomal damage in neurodegeneration

NDs are fatal progressive disorders characterized by the loss of functionality and/or the death of specific subpopulations of neurons controlling cognitive or motor functions. Different pathological mechanisms induce neuronal death, among which alteration in proteostasis is of great relevance. Proteostasis dysfunction coincides with the generation of damaged organelles involved in the protein quality control (PQC), variation in the expression of contributors to PQC, and the formation of protein aggregates which may ultimately lead to cell death through different mechanisms [134–137]. The most common NDs, depicted in Fig. 2, include Parkinson’s disease (PD), Huntington’s disease (HD), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and Alzheimer’s disease (AD). Their classification is based on primary clinical features, anatomical distribution of neuronal degeneration, and the main molecular alterations that characterize each of them. Although these NDs differ significantly in etiopathogenesis and clinical aspects, they generally present certain common cellular and molecular alterations such as protein aggregation, impairment of degradative systems, and damage to degradation-related organelles such as lysosomes. Indeed, emerging evidence suggests that lysosomal dysfunction is strictly correlated with the pathogenesis of these diseases, either as a trigger or a consequence of neuronal or microglial cell dysfunction. LMP and leakage of lysosomal contents, including cathepsin B and calcium, have been observed in various NDs [138–140]. As shown in Table 1, lysosomal damage is associated with ND-related mutations in genes encoding proteins directly involved in lysosomal membrane integrity and lysosomal functionality. These include lysosomal transmembrane proteins such as transmembrane protein (TMEM) 106B and ATPase cation transporting 13A2 (ATP13A2) [141, 142]; or proteins implicated in lysosome repair or degradation, such as LRRK2 and VCP, SQSTM1/p62, OPTN, or TBK1 [143–146] (see below for further details). Of note, neurons can uptake extracellular aggregates through endocytosis; depending upon their nature and biophysical properties, these aggregates can induce lysosomal membrane rupture [55]. Proteins implicated in this mechanism can be found in Table 2. The lysosomal toxicity of protein aggregates has been directly demonstrated for various ND-related proteins, including alpha-synuclein (SNCA), β-amyloid (Aβ), tau, and superoxide dismutase 1 [83, 140, 147–149]. Together, these findings show a strong interaction between lysosomal alterations and NDs. Table 1 Genes mutated in NDs that are involved with lysosomes alterations

Gene	Role	ND-related	References	
LRRK2	-Recruits and phosphorylates RAB proteins to regulate lysosomal repair

-Maintains lysosome pH by interacting with vATPase a1 subunit

	PD	[160, 224, 225]	
ATP13A2	P-type ATPase which maintains lysosome pH	PD	[226]	
GBA	Lysosomal enzyme degrading glycolipids	PD	[227]	
TMEM175	Ion channel that contributes in maintaining lysosomal pH	PD	[228]	
SCARB2	Phospholipid receptor regulator of lysosome-cholesterol interaction	PD	[165]	
SQSTM1/p62	AR that mediates damaged lysosome engulfment in autophagosomes	ALS/FTD	[144, 229]	
UBQLN2	Interacts with v-ATPase contributing in lysosomal pH	ALS/FTD	[230, 231]	
DCTN1	Binds damaged lysosome and promotes their addressing to autophagy degradation	ALS/FTD	[232]	
TBK1	Phosphorylates AR regulating lysosome degradation	ALS/FTD	[233, 234]	
OPTN	AR that mediates damaged lysosome engulfment in autophagosomes	ALS/FTD/PD	[145, 188]	
VCP	Mediates degradation of lysosomal membrane proteins promoting lysosome degradation	ALS/FTD	[146, 235]	
TMEM106B	Lysosomal transmembrane protein, regulates lysosomal morphology, acidification and transport	FTD	[236]	
MFSD8	Lysosomal transmembrane protein, indirect regulator of lysosomal calcium content and activity	ALS/FTD	[191, 237]	
CTSF	Lysosomal enzyme degrading proteins	FTD	[193]	
PGRN	Modulates lysosome enzymes activity	FTD	[238]	
PSEN1	Transmembrane protein with enzymatic activity degrading proteins	AD	[239]	

Table 2 Genes mutated in NDs which induce lysosome alterations

Gene	Role in lysosome damage	ND-related	References	
SNCA	Toxicity mediated by aggregation	PD	[54, 171]	
C9ORF72	Toxicity mediated by aggregation	ALS/FTD	[240]	
TARDBP	Toxicity mediated by aggregation and loss of function	ALS/FTD	[195, 196]	
MAPT	Toxicity mediated by aggregation and loss of function	FTD/ALS	[199, 200]	
FUS	Toxicity mediated by aggregation	ALS	[202]	
IT15	Toxicity mediated by aggregation	HD	[241]	
APP	Toxicity mediated by aggregation	AD	[215]	

Parkinson’s disease

PD is the most common ND, affecting 1% of the population over 65 years old. The clinical manifestations of the disease can vary among individuals. The most recurrent symptoms and signs include bradykinesia, tremors, muscular rigidity, and speech and cognitive impairments [150]. The histopathological hallmark of PD is the presence of Lewy body (LBs) inclusions, which result from intracellular accumulation of SNCA. LBs are associated with the death of dopaminergic neurons present in the substantia nigra [151]. Other hallmarks of PD include a correlation of the disease with lysosome alterations, such as increased galectin-3 plasma levels, which has been proposed as a potential biomarker to monitor PD-related neurodegeneration [152]. Moreover, patients exhibit an overactivation of microglia that leads to an inflammatory response. The activation of microglia is also associated with lysosomal alterations mediated by galectin-3 [153, 154].

Only 10% of PD cases occur in familiar forms, while 90% are sporadic. To date, a large part of the genetic causes of PD has still to be identified. Approximately 5–10% of hereditary PD cases are associated with identified mutations in genes such as SNCA, LRRK2, and PRKN [155, 156]. Conversely, in most cases, PD etiology is multifactorial and involves an interplay between environmental and genetic factors. Genome-wide association studies have identified various risk genes and loci linked to PD [157, 158]; several have a strong link to lysosomes (as reviewed in [159]). In particular, LRRK2 encodes for a protein involved in lysosome repair thanks to its phosphorylation and interaction with RAB29, which also interacts directly with the a1 subunit of the vacuolar-type ATPase H+ pump that maintains lysosomal pH [72, 160, 161]. Other relevant genes are ATP13A2, encoding for a cation transporter that maintains the proper pH in lysosomes [162]; GBA, encoding for glucocerebrosidase, a lysosomal enzyme that converts glucosylceramide and is involved in lysosome activity [163]; TMEM175, encoding for a lysosome channel regulator of potassium in lysosomes [164]; and SCARB2, encoding for a structural transmembrane lysosomal protein, which acts as a regulator of cholesterol-membrane composition and a receptor of β-glucocerebrosidase, which in turn controls the clearance of SNCA [165–167]. This long list of genes supports the notion that alterations of lysosome function and dynamics may contribute to PD onset and disease progression. Additionally, other elements correlate PD and lysosome disruption, such as the close relationship between lysosomes misfunctioning and SNCA. This is evidenced by several facts: that lysosomes are essential for SNCA degradation [168] and their alterations or the accumulation of lysosomal substrates result in increased SNCA cytoplasmatic levels, triggering the pathological aggregation [169–171]; that other key players in lysosome repair and clearance, such as galectin-3 and TRIM16, have been shown to promote SNCA release and its spreading into the extracellular environment upon lysosomal damage and to promote SNCA conversion into fibrils [54, 152, 153]; and that SNCA aggregation can alter the autophagic-lysosomal pathway either by directly disrupting lysosomal components or by inhibiting trafficking events [147, 168, 172]. Altogether, these findings show a dual interaction between SNCA aggregation and lysosome functionality, underlying a crucial correlation between them.

Frontotemporal dementia and amyotrophic lateral sclerosis

FTD and ALS are two distinct NDs that display overlapping clinical signs and pathological mechanisms [173]. FTD primarily affects the frontal and temporal lobes of the brain, leading to changes in behavior, personality, and language skills accompanied by a decline in social cognition, emotional regulation, and executive functions [174]. ALS mainly affects motor neurons, responsible for voluntary muscle control, leading to muscle weakness and paralysis, and impairs the ability to speak, swallow, and breathe [175]. Both FTD and ALS present familial (fFTD and fALS) and sporadic (sFTD and sALS) forms. Although FTD and ALS are distinct diseases, they belong to a spectrum of diseases known as FTD/ALS, which highlights their overlapping nature.

FTD and ALS exhibit common molecular pathological features, including the mislocalization and aggregation of TAR DNA-binding protein 43 (TDP-43), a ribonucleotide protein that regulates mRNA metabolism, the accumulation of FTD/ALS-associated mutated proteins in inclusions, and the failure of the PQC system [173, 176, 177]. FTD/ALS are also associated with alterations to the autophagy–lysosomal pathway, detectable in postmortem tissue of FTD/ALS patients [87, 178] and evidenced by increased levels of galectin-3 in the spinal cord and cerebrospinal fluid, suggesting changes in lysosome dynamics [178, 179].

FTD and ALS also overlap at the genetic level; roughly 30% of fFTD cases, 5–10% of sALS cases, and approximately 50% of fALS cases are linked to a mutation in the C9ORF72 gene [173, 180]. This mutation involves the abnormal expansion of a hexanucleotide sequence (G4C2) localized in the first C9ORF72 intron. This mutation triggers three pathological mechanisms, one related to a loss of function due to haploinsufficiency and the other two involving a gain of toxicity. The toxicity may be caused either by the formation of aberrant RNA foci in the nucleus or by an unconventional repeat-associated ATG-independent (RAN) translation, which leads to the production of five different dipeptide repeat proteins. C9ORF72, known as a regulator of autophagic flux, plays a crucial role in maintaining the proper functionality of the autophagy-lysosomal pathway [181]. Haploinsufficiency of C9ORF72 causes the impairment of autophagy and lysosome functions, resulting in the accumulation of lysosome-like organelles that precede neurodegeneration, thereby contributing to the pathogenesis of FTD and ALS (reviewed in [182]). These phenotypes are partially caused by a decreased TFEB expression and by its cytoplasmic retention [183].

Other genes associated with FTD and ALS cases, including SQSTM1/p62, UBQLN2, DCTN1, TBK1, OPTN, and VCP [184–189], have been previously described to play a role in autophagy. Moreover, other genes associated exclusively with FTD are implicated in lysosomal trafficking, including TMEM106B and the major facilitator superfamily domain containing 8 (MFSD8) or in lysosomal activity, such as Cathepsin F (Ctsf) and granulin precursor (GRN) [190–193]. Thus, mutations in genes associated with lysosomal stability, functioning, or degradation underline an important implication of lysosomes and autophagy in pathological neurodegenerative mechanisms.

Lysosomal alterations in FTD/ALS can also be caused by a gain of toxicity associated with an increased toxic aggregation of TDP-43, mutated proteins such as tau, a microtubule-associated protein, or fused in sarcoma (FUS), a protein involved in regulating RNA metabolism. The aggregation of TDP-43 alters a specific autophagic pathway, chaperone-mediated autophagy (CMA), and disrupts lysosome function, which in turn exacerbates TDP-43 toxicity and loss of function [194, 195]. Indeed, TDP-43 aggregation and functional loss are associated with the activation of autophagosome and lysosome biogenesis through the inhibition of mTORC1 and activation of TFEB. Simultaneously, TDP-43 loss of function causes impairment in the fusion of autophagosomes with lysosomes, via an mTORC1-independent mechanism. Consequently, the buildup of AVs contributes to the aggregation of TDP-43 and neurodegeneration [196]. The aggregation of tau also impairs lysosomal functions through various mechanisms. In physiological conditions, tau stabilizes microtubules, facilitating the proper trafficking and maintenance of lysosomes [197, 198]. However, FTD-associated tau mutants are prone to aggregate, leading to hyperphosphorylation, ubiquitination, and destabilization of microtubules [199]. Moreover, tau aggregates also inhibit IST1, a member of the ESCRT complex, block CMA, and impair lysosome function. This results in the formation of enlarged dysfunctional lysosomes and even their rupture [200, 201]. Similarly, to tau, mutated FUS forms protein aggregates. These aggregates may sequester LAMP-1-positive structures, leading to the aberrant accumulation of functional lysosomes around the abnormal FUS aggregates [202].

Huntington’s disease

HD is characterized by the progressive deterioration of cognitive, motor, and psychiatric functions. As the disease progresses, HD symptoms include involuntary movements (chorea), cognitive decline, psychiatric disturbances, and difficulties with speech and swallowing [203]. HD is an inherited condition caused by an expansion of CAG trinucleotide repeats in the Huntingtin (HTT) gene, resulting in the production of an abnormal form of the HTT protein containing an elongated polyglutamine tract. The mutation leads to the accumulation of toxic protein aggregates in the brain, particularly in the basal ganglia and cortex (Fig. 2). HD displays several hallmarks of impairments in lysosomal function and dynamics. For instance, galectin-3 levels increase in the brains of HD mice and patients, suggesting alterations to lysosome activity. Galectin-3 levels increase in microglia before the onset of the disease and mediate the initiation of the inflammatory response which contribute to HD pathogenesis [204]. Moreover, an increase in the perinuclear accumulation of lysosomes is visible in HD models and it is normalized upon the overexpression of wild-type HTT. Mutant HTT (mHTT)-induced lysosome accumulation is associated with an increase in mTORC1 basal activity and the autophagic flux, resulting in a premature fusion of lysosomes with autophagosomes [205]. To further emphasize the autophagy–lysosome connection with HD, mHTT is recruited to vesicle-rich organelles that resemble multivesicular bodies or autolysosomes, suggesting a lysosome-dependent degradation of mHTT [206]. In addition, lysosomes are implicated in mHTT removal through an unconventional lysosome-dependent secretion mechanism [207].

These findings underscore the importance of an autophagy-lysosome role in HD and provide insights into potential therapeutic targets for the disease.

Alzheimer’s disease

AD is the most common cause of dementia and primarily affects memory, cognitive abilities, and behavior, gradually impairing daily functioning. AD typically starts with mild memory loss and progresses to severe cognitive decline and loss of independence [208]. The exact cause of AD is not fully understood, but age, genetic factors (such as the apolipoprotein E ε4 allele), and certain lifestyle and environmental factors are believed to play a role in AD pathogenesis [209]. AD is characterized by the accumulation of abnormal protein aggregates in the brain, such as Aβ plaques and tau tangles. Like in the previously discussed NDs, AD also presents signs of altered autophagy–lysosome pathways. This evidence includes galectin-3 accumulation in Aβ plaques in microglia, mediating the maladaptive activation of the inflammatory response [210]; dysregulation in endosome– and lysosome–ER contact sites due to amyloid precursor protein (APP) [211]; increased alkalinization in neuronal lysosomes which appears before Aβ deposition outside the cells. Lysosomal pH alteration is caused by decreased v-ATPase activity, associated with presenilin-1 mutations, and the accumulation of Aβ within enlarged autolysosomes that have lost their acidity. In line with this, in vitro studies have shown that the reacidification of lysosomes rescues lysosome dysfunction and accumulation [212]. Moreover, in affected neurons, AVs containing Aβ accumulate in a tightly packed manner within large membrane protrusions [213–215]. Similar observations have been described in the brains of AD patients. Additional AVs merge to form networks of membrane tubules surrounding the nucleus, where fibrillar Aβ accumulates within the lumens. This leads to the disruption of lysosomal membranes, the release of cathepsins, and ultimately cell death, accompanied by the invasion of microglial cells [215]. Recently it was found that positive modulation of TRIM16-mediated lysophagy decreases the accumulation of Aβ/tau, further underlying the tight connection between lysosome alterations and AD pathology [216].

Conclusions

Lysosomes are essential organelles for cell viability and alterations in their function are associated with several diseases, including LSDs and NDs. Indeed, accumulating evidence suggests that maintaining lysosomal integrity and efficient lysosomal degradation processes is crucial for neuronal protection and the prevention of NDs. To maintain homeostasis, cells activate different complex mechanisms to repair damaged lysosomes or, when this is not possible, to clear them away through lysophagy or exocytosis. These crucial processes are finely regulated by various proteins and complexes. However, many aspects of these processes remain unknown or not fully understood. Thus, unraveling the complex interplay between lysosomal dysfunction, aggregates accumulation, inflammation, and neuronal cells death holds promise for identifying novel therapeutic targets and developing strategies to counteract or slow down ND progression.

Some steps in this direction have already been taken, and therapeutic approaches and molecules that facilitate lysosomal clearance or biogenesis have been identified. Notably, certain molecules activate lysosome biogenesis by promoting the nuclear localization of TFEB. For example, compounds such as PP 242 and LY 294002 activate TFEB by inhibiting mTOR [217, 218]. Other substances, such as trehalose and its analogs lactulose and melibiose, enhance TFEB activity through an mTOR-independent pathway, as described in ref. [219]. The use of these compounds in disease models has shown promising results, encouraging research in this direction [220–223].

Altogether, this review highlights the intricate nature of the mechanisms governing lysosomal function and dynamics, as well as the consequence of their dysfunction in the development of pathological conditions. The complexity and significance of the described mechanisms underline the necessity of further investigation to enhance our understanding of pathological processes and development of therapeutic strategies.

Abbreviations

AD Alzheimer’s disease

Aβ amyloid β

ALR Autophagic lysosome reformation

ALS Amyotrophic lateral sclerosis

AMPK AMP-activated Protein Kinase

APP Amyloid precursor protein

AR Autophagy receptor

ATG Autophagy-related

ATP13A2 ATPase cation transporting 13A2

AV Autophagic vacuole

CALCOCO2/NDP52 Calcium-binding and coiled-coil domain 2 protein

CASM Conjugation of ATG8s to single membranes

CHMP4B Charged multivesicular body protein 4B

CLEAR Coordinated lysosomal expression and regulation

CMA Chaperone-mediated autophagy

ESCRT Endosomal sorting complex required for transport

ER Endoplasmic reticulum

FTD Frontotemporal dementia

FUS Fused in sarcoma

GBA Glucocerebrosidase

GRN Granulin precursor

HD Huntington’s disease

HDAC Histone deacetylases

HSPA8 Heat shock protein family A (Hsp70) member 8

HTT Huntingtin

ILVs Intraluminal vesicles

IPMK Inositol polyphosphate multikinase

KIF5B Kinesin family member 5B

LAMP1 Lysosomal associated membrane protein 1

LAMP2A Lysosome-associated membrane protein 2A

LB Lewy body

LGALS3 Galectin 3

LIMP Lysosomal integral membrane proteins

LLPS Liquid–liquid phase separation

LMP Lysosomal membrane permeabilization

LQC Lysosomal quality control

LRRK2 Leucine-rich repeat kinase 2

LSDs Lysosomal storage disorders

LYTL Lysosomal tubulation sorting

MAP1LC3 Microtubule Associated Protein 1 Light Chain 3 Beta

MAP3K7/TAK1 Mitogen-activated protein kinase kinase kinase 7

MAPK1 Mitogen-activated protein kinase 1

MCOLN1 Mucolipin TRP cation channel 1

MCS Membrane contact sites

MFSD8 Major facilitator superfamily domain containing 8

mTOR Mechanistic target of rapamycin

NDs Neurodegenerative diseases

OPTN Optineurin

OSBP Oxysterol binding protein

PD Parkinson’s disease

PDCD6IP/ALIX Programmed cell death 6 interacting protein

PI Phosphatidyl-inositol

PI4K2A Phosphatidyl-inositol-4 kinase type 2 alpha

PI4P Phosphatidyl-inositol 4-phosphate

PITT Phosphoinositide-initiated membrane tethering and lipid transport

PPP3CB Protein phosphatase 3 catalytic subunit beta

PQC Protein quality control

PS Phosphatidyl-serine

RAN Repeat-associated ATG independent

SMURF1 SMAD specific E3 ubiquitin-protein ligase

SNCA Alpha-synuclein

SQSTM1/p62 Sequestosome 1

TARDBP/TDP-43 TAR DNA binding protein

TBK1 TANK-binding kinase 1

TFE3 Transcription factor E3

TFEB Transcription factor EB

TMEM Transmembrane protein

TRIM16 Tripartite motif-containing 16

UBA Ubiquitin-associated

USP9X Ubiquitin-specific peptidase 9 X linked

VCP Valosin containing protein

Author contributions

V.F. and P.R. drafted and supervised the manuscript. A.P. supervised and revised the manuscript. B.T., M.Co., M.Ch., and E.C. performed literature search. P.P., L.C., G.P., A.M., and M.P. prepared the figures and the tables. R.C., M.G., and V.C. revised the manuscript. All authors read and approved the final version of the manuscript.

Funding

This study was supported by: Fondazione Telethon—Italy (n. GGP19128 to A.P.); Fondazione Cariplo—Italy (n. 2021–1544 to R.C.); Fondazione Italiana di Ricerca per la Sclerosi Laterale Amiotrofica (AriSLA)—Italy (n. MLOpathy to A.P.; Target-RAN to A.P.); Association Française contre les Myopathies—France (AFM Telethon n. 23236 to A.P.); Kennedy’s Disease Association—USA (2018 grant to RC; 2020 grant to M.G.); Ministero dell’Università e della Ricerca (MIUR)—Italy [PRIN—Progetti di ricerca di interesse nazionale (n. 2017F2A2C5 to A.P.; n. 2022EFLFL8 to A.P.; n. 2020PBS5MJ to V.C.; n.2022KSJZF5 to V.C.); PRIN—Progetti di ricerca di interesse nazionale—bando 2022, PNRR finanziato dall’Unione europea—Next Generation EU, componente M4C2, investimento 1.1 (n. P2022B5J32 to R.C. and n. P20225R4Y5 to V.C.); CN3: RNA—Codice Proposta: CN_00000041; Tematica Sviluppo di terapia genica e farmaci con tecnologia a RNA (Centro Nazionale di Ricerca—CN3 National Center for Gene Therapy and Drugs based on RNA Technology to A.P.); Progetto Dipartimenti di Eccellenza to Di.S.Fe.B.]; Ministero della Salute, Agenzia Italiana del Farmaco (AIFA)—Italy (Co_ALS to A.P.); Università degli Studi di Milano [piano di sviluppo della ricerca (PSR) UNIMI—linea B to R.C., B.T., and V.F.]; the University of Milan through the APC initiative.

Data availability

Not applicable.

Declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Angelo Poletti and Paola Rusmini contributed equally to the work.
==== Refs
References

1. De Duve C Wattiaux R Functions of lysosomes Annu Rev Physiol 1966 28 435 492 10.1146/annurev.ph.28.030166.002251 5322983
De Duve C, Wattiaux R. Functions of lysosomes. Annu Rev Physiol. 1966;28:435–92.5322983 10.1146/annurev.ph.28.030166.002251
2. De Duve C Pressman BC Gianetto R Wattiaux R Applemans F Tissue fractionation studies. 6. Intracellular distribution patterns of enzymes in rat-liver tissue Biochem J. 1955 60 4 604 617 10.1042/bj0600604 13249955
De Duve C, Pressman BC, Gianetto R, Wattiaux R, Applemans F. Tissue fractionation studies. 6. Intracellular distribution patterns of enzymes in rat-liver tissue. Biochem J. 1955;60(4):604–17. 10.1042/bj0600604.13249955 10.1042/bj0600604
3. Seglen PO Gordon PBHI Non-selective autophagy Semin Cell Biol 1990 1 6 441 448 2103895
Seglen PO, Gordon PBHI. Non-selective autophagy. Semin Cell Biol. 1990;1(6):441–8.2103895
4. Sancak Y Bar-Peled L Zoncu R Markhard AL Nada S Sabatini DM Ragulator-Rag complex targets mTORC1 to the lysosomal surface and is necessary for its activation by amino acids Cell 2010 141 2 290 303 10.1016/j.cell.2010.02.024 20381137
Sancak Y, Bar-Peled L, Zoncu R, Markhard AL, Nada S, Sabatini DM. Ragulator-Rag complex targets mTORC1 to the lysosomal surface and is necessary for its activation by amino acids. Cell. 2010;141(2):290–303.20381137 10.1016/j.cell.2010.02.024
5. Zoncu R Bar-Peled L Efeyan A Wang S Sancak Y Sabatini DM mTORC1 senses lysosomal amino acids through an inside-out mechanism that requires the vacuolar H±ATPase Science 2011 334 6056 678 83 10.1126/science.1207056 22053050
Zoncu R, Bar-Peled L, Efeyan A, Wang S, Sancak Y, Sabatini DM. mTORC1 senses lysosomal amino acids through an inside-out mechanism that requires the vacuolar H±ATPase. Science. 2011;334(6056):678–83.22053050 10.1126/science.1207056
6. Gray MA Choy CH Dayam RM Escobar EO Somerville A Xiao X Phagocytosis enhances lysosomal and bactericidal properties by activating the transcription factor TFEB Matthew Curr Biol 2017 26 15 1955 64 10.1016/j.cub.2016.05.070
Gray MA, Choy CH, Dayam RM, Escobar EO, Somerville A, Xiao X, et al. Phagocytosis enhances lysosomal and bactericidal properties by activating the transcription factor TFEB Matthew. Curr Biol. 2017;26(15):1955–64.10.1016/j.cub.2016.05.070
7. Reddy A Caler EV Andrews NW Haven N Plasma membrane repair is mediated by Ca 2 ± regulated exocytosis of lysosomes Cell 2001 106 157 69 10.1016/S0092-8674(01)00421-4 11511344
Reddy A, Caler EV, Andrews NW, Haven N. Plasma membrane repair is mediated by Ca 2 ± regulated exocytosis of lysosomes. Cell. 2001;106:157–69.11511344 10.1016/S0092-8674(01)00421-4
8. Encarnação M Espada L Escrevente C Mateus D Ramalho J Michelet X A Rab3a-dependent complex essential for lysosome positioning and plasma membrane repair J Cell Biol 2016 10.1083/jcb.201511093 27325790
Encarnação M, Espada L, Escrevente C, Mateus D, Ramalho J, Michelet X, et al. A Rab3a-dependent complex essential for lysosome positioning and plasma membrane repair. J Cell Biol. 2016. 10.1083/jcb.201511093.27325790 10.1083/jcb.201511093
9. Lim CY Zoncu R The lysosome as a command-and-control center for cellular metabolism J Cell Biol 2016 214 6 653 64 10.1083/jcb.201607005 27621362
Lim CY, Zoncu R. The lysosome as a command-and-control center for cellular metabolism. J Cell Biol. 2016;214(6):653–64.27621362 10.1083/jcb.201607005
10. Lawrence RE Zoncu R The lysosome as a cellular centre for signalling, metabolism and quality control Nat Cell Biol 2019 21 2 133 142 10.1038/s41556-018-0244-7 30602725
Lawrence RE, Zoncu R. The lysosome as a cellular centre for signalling, metabolism and quality control. Nat Cell Biol. 2019;21(2):133–42.30602725 10.1038/s41556-018-0244-7
11. Repnik U Česen MH Turk B The endolysosomal system in cell death and survival Cold Spring Harb Perspect Biol 2013 5 1 a008755 10.1101/cshperspect.a008755 23284043
Repnik U, Česen MH, Turk B. The endolysosomal system in cell death and survival. Cold Spring Harb Perspect Biol. 2013;5(1): a008755.23284043 10.1101/cshperspect.a008755
12. Sun A Lysosomal storage disease overview Ann Transl Med 2018 10.21037/atm.2018.11.39 30740437
Sun A. Lysosomal storage disease overview. Ann Transl Med. 2018. 10.21037/atm.2018.11.39.30740437 10.21037/atm.2018.11.39
13. Parenti G Andria G Ballabio A Lysosomal storage diseases : from pathophysiology to therapy Annu Rev Med 2015 10.1146/annurev-med-122313-085916 25587658
Parenti G, Andria G, Ballabio A. Lysosomal storage diseases : from pathophysiology to therapy. Annu Rev Med. 2015. 10.1146/annurev-med-122313-085916.25587658 10.1146/annurev-med-122313-085916
14. Marques ARA Saftig P Lysosomal storage disorders—challenges, concepts and avenues for therapy: beyond rare diseases J Cell Sci 2019 10.1242/jcs.221739 30651381
Marques ARA, Saftig P. Lysosomal storage disorders—challenges, concepts and avenues for therapy: beyond rare diseases. J Cell Sci. 2019. 10.1242/jcs.221739.30651381 10.1242/jcs.221739
15. Kirkegaard T Jäättelä M Biochimica et biophysica acta lysosomal involvement in cell death and cancer BBA Mol Cell Res 2009 1793 4 746 754
Kirkegaard T, Jäättelä M. Biochimica et biophysica acta lysosomal involvement in cell death and cancer. BBA Mol Cell Res. 2009;1793(4):746–54.
16. Davidson SM Vander HMG Critical functions of the lysosome in cancer biology Annu Rev Pharmacol Toxicol 2017 57 481 510 10.1146/annurev-pharmtox-010715-103101 27732799
Davidson SM, Vander HMG. Critical functions of the lysosome in cancer biology. Annu Rev Pharmacol Toxicol. 2017;57:481–510.27732799 10.1146/annurev-pharmtox-010715-103101
17. Herbst S Campbell P Harvey J Bernard EM Papayannopoulos V Wood NW LRRK 2 activation controls the repair of damaged endomembranes in macrophages EMBO J 2020 39 18 1 14 10.15252/embj.2020104494
Herbst S, Campbell P, Harvey J, Bernard EM, Papayannopoulos V, Wood NW, et al. LRRK 2 activation controls the repair of damaged endomembranes in macrophages. EMBO J. 2020;39(18):1–14.10.15252/embj.2020104494
18. Feng T Mai S Roscoe JM Sheng RR Ullah M Zhang J Loss of TMEM106B and PGRN leads to severe lysosomal abnormalities and neurodegeneration in mice EMBO Rep 2020 21 10 e50219 10.15252/embr.202050219 32852886
Feng T, Mai S, Roscoe JM, Sheng RR, Ullah M, Zhang J, et al. Loss of TMEM106B and PGRN leads to severe lysosomal abnormalities and neurodegeneration in mice. EMBO Rep. 2020;21(10): e50219.32852886 10.15252/embr.202050219
19. Tedeschi V Petrozziello T Secondo A Calcium dyshomeostasis and lysosomal Ca2+ dysfunction in amyotrophic lateral sclerosis Cells 2019 10.3390/cells8101216 31597311
Tedeschi V, Petrozziello T, Secondo A. Calcium dyshomeostasis and lysosomal Ca2+ dysfunction in amyotrophic lateral sclerosis. Cells. 2019. 10.3390/cells8101216.31597311 10.3390/cells8101216
20. Cortes CJ La Spada AR TFEB dysregulation as a driver of autophagy dysfunction in neurodegenerative disease: molecular mechanisms, cellular processes, and emerging therapeutic opportunities Neurobiol Dis 2018 10.1016/j.nbd.2018.05.012 29852219
Cortes CJ, La Spada AR. TFEB dysregulation as a driver of autophagy dysfunction in neurodegenerative disease: molecular mechanisms, cellular processes, and emerging therapeutic opportunities. Neurobiol Dis. 2018. 10.1016/j.nbd.2018.05.012.29852219 10.1016/j.nbd.2018.05.012
21. Wang Y Martinez-Vicente M Krüger U Kaushik S Wong E Mandelkow EM Tau fragmentation, aggregation and clearance: the dual role of lysosomal processing Hum Mol Genet 2009 18 21 4153 4170 10.1093/hmg/ddp367 19654187
Wang Y, Martinez-Vicente M, Krüger U, Kaushik S, Wong E, Mandelkow EM, et al. Tau fragmentation, aggregation and clearance: the dual role of lysosomal processing. Hum Mol Genet. 2009;18(21):4153–70.19654187 10.1093/hmg/ddp367
22. Dodson MW Zhang T Jiang C Chen S Guo M Roles of the Drosophila LRRK2 homolog in Rab7-dependent lysosomal positioning Hum Mol Genet 2012 21 6 1350 1363 10.1093/hmg/ddr573 22171073
Dodson MW, Zhang T, Jiang C, Chen S, Guo M. Roles of the Drosophila LRRK2 homolog in Rab7-dependent lysosomal positioning. Hum Mol Genet. 2012;21(6):1350–63.22171073 10.1093/hmg/ddr573
23. Tohnai G Adachi H Katsuno M Doi H Matsumoto S Kondo N Paeoniflorin eliminates a mutant AR via NF-YA-dependent proteolysis in spinal and bulbar muscular atrophy Hum Mol Genet 2014 10.1093/hmg/ddu066 25168383
Tohnai G, Adachi H, Katsuno M, Doi H, Matsumoto S, Kondo N, et al. Paeoniflorin eliminates a mutant AR via NF-YA-dependent proteolysis in spinal and bulbar muscular atrophy. Hum Mol Genet. 2014. 10.1093/hmg/ddu066.25168383 10.1093/hmg/ddu066
24. Mathis S Goizet C Soulages A Vallat JM Le MG Genetics of amyotrophic lateral sclerosis: a review J Neurol Sci 2019 399 February 217 226 10.1016/j.jns.2019.02.030 30870681
Mathis S, Goizet C, Soulages A, Vallat JM, Le MG. Genetics of amyotrophic lateral sclerosis: a review. J Neurol Sci. 2019;399(February):217–26.30870681 10.1016/j.jns.2019.02.030
25. Carmona-gutierrez D Hughes AL Madeo F Ruckenstuhl C The crucial impact of lysosomes in aging and longevity Age Res Rev 2016 32 2 12 10.1016/j.arr.2016.04.009
Carmona-gutierrez D, Hughes AL, Madeo F, Ruckenstuhl C. The crucial impact of lysosomes in aging and longevity. Age Res Rev. 2016;32:2–12.10.1016/j.arr.2016.04.009
26. Peters C von Figura K Biogenesis of lysosomal membranes FEBS Lett 1994 346 1 108 114 10.1016/0014-5793(94)00499-4 8206148
Peters C, von Figura K. Biogenesis of lysosomal membranes. FEBS Lett. 1994;346(1):108–14.8206148 10.1016/0014-5793(94)00499-4
27. Schwake M Schröder B Saftig P Lysosomal membrane proteins and their central role in physiology Traffic 2013 14 7 739 748 10.1111/tra.12056 23387372
Schwake M, Schröder B, Saftig P. Lysosomal membrane proteins and their central role in physiology. Traffic. 2013;14(7):739–48.23387372 10.1111/tra.12056
28. Schröder B Wrocklage C Pan C Jäger R Kösters B Schäfer H Integral and associated lysosomal membrane proteins Traffic 2007 8 12 1676 1686 10.1111/j.1600-0854.2007.00643.x 17897319
Schröder B, Wrocklage C, Pan C, Jäger R, Kösters B, Schäfer H, et al. Integral and associated lysosomal membrane proteins. Traffic. 2007;8(12):1676–86.17897319 10.1111/j.1600-0854.2007.00643.x
29. Schröder BA Wrocklage C Hasilik A Saftig P The proteome of lysosomes Proteomics 2010 10 22 4053 4076 10.1002/pmic.201000196 20957757
Schröder BA, Wrocklage C, Hasilik A, Saftig P. The proteome of lysosomes. Proteomics. 2010;10(22):4053–76.20957757 10.1002/pmic.201000196
30. Lewis V Green SA Marsh M Vlhko P Helenius A Mellman I Glycoproteins of the lysosomal membrane J Cell Biol 1985 100 6 1839 1847 10.1083/jcb.100.6.1839 3922993
Lewis V, Green SA, Marsh M, Vlhko P, Helenius A, Mellman I. Glycoproteins of the lysosomal membrane. J Cell Biol. 1985;100(6):1839–47.3922993 10.1083/jcb.100.6.1839
31. Andrejewski N Punnonen EL Guhde G Tanaka Y Lüllmann-Rauch R Hartmann D Normal lysosomal morphology and function in LAMP-1-deficient mice J Biol Chem 1999 274 18 12692 12701 10.1074/jbc.274.18.12692 10212251
Andrejewski N, Punnonen EL, Guhde G, Tanaka Y, Lüllmann-Rauch R, Hartmann D, et al. Normal lysosomal morphology and function in LAMP-1-deficient mice. J Biol Chem. 1999;274(18):12692–701.10212251 10.1074/jbc.274.18.12692
32. Tanaka Y Guhde G Suter A Eskelinen EL Hartmann D Lüllmann-Rauch R Accumulation of autophagic vacuoles and cardiomyopathy LAMP-2-deficient mice Nature 2000 406 6798 902 906 10.1038/35022595 10972293
Tanaka Y, Guhde G, Suter A, Eskelinen EL, Hartmann D, Lüllmann-Rauch R, et al. Accumulation of autophagic vacuoles and cardiomyopathy LAMP-2-deficient mice. Nature. 2000;406(6798):902–6.10972293 10.1038/35022595
33. Nishino I Autophagic vacuolar myopathy Semin Pediatr Neurol 2006 13 2 90 5 10.1016/j.spen.2006.06.004 17027858
Nishino I. Autophagic vacuolar myopathy. Semin Pediatr Neurol. 2006;13(2):90–5.17027858 10.1016/j.spen.2006.06.004
34. Xu J Wang L Liu X Dai Q A novel LAMP2 p.G93R mutation associated with mild Danon disease presenting with familial hypertrophic cardiomyopathy Mol Genet Genomic Med 2019 7 10 e00941 10.1002/mgg3.941 31464081
Xu J, Wang L, Liu X, Dai Q. A novel LAMP2 p.G93R mutation associated with mild Danon disease presenting with familial hypertrophic cardiomyopathy. Mol Genet Genomic Med. 2019;7(10):e00941.31464081 10.1002/mgg3.941
35. Kolter T Sandhoff K Principles of lysosomal membrane digestion: stimulation of sphingolipid degradation by sphingolipid activator proteins and anionic lysosomal lipids Annu Rev Cell Dev Biol 2005 21 1 81 103 10.1146/annurev.cellbio.21.122303.120013 16212488
Kolter T, Sandhoff K. Principles of lysosomal membrane digestion: stimulation of sphingolipid degradation by sphingolipid activator proteins and anionic lysosomal lipids. Annu Rev Cell Dev Biol. 2005;21(1):81–103.16212488 10.1146/annurev.cellbio.21.122303.120013
36. Rudnik S Damme M The lysosomal membrane—export of metabolites and beyond FEBS J 2021 288 14 4168 4182 10.1111/febs.15602 33067905
Rudnik S, Damme M. The lysosomal membrane—export of metabolites and beyond. FEBS J. 2021;288(14):4168–82.33067905 10.1111/febs.15602
37. Kobayashi T Stang E Fang KS de Moerloose P Parton RG Gruenberg J A lipid associated with the antiphospholipid syndrome regulates endosome structure and function Nature 1998 392 6672 193 197 10.1038/32440 9515966
Kobayashi T, Stang E, Fang KS, de Moerloose P, Parton RG, Gruenberg J. A lipid associated with the antiphospholipid syndrome regulates endosome structure and function. Nature. 1998;392(6672):193–7.9515966 10.1038/32440
38. van Meer G Voelker DRFG Membrane lipids: where they are and how they behave Nat Rev Mol Cell Biol 2008 9 2 112 124 10.1038/nrm2330 18216768
van Meer G, Voelker DRFG. Membrane lipids: where they are and how they behave. Nat Rev Mol Cell Biol. 2008;9(2):112–24.18216768 10.1038/nrm2330
39. Schoer JK Gallegos AM McIntosh AL Starodub O Kier AB Billheimer JT Lysosomal membrane cholesterol dynamics Biochemistry 2000 39 26 7662 7677 10.1021/bi992686h 10869172
Schoer JK, Gallegos AM, McIntosh AL, Starodub O, Kier AB, Billheimer JT, et al. Lysosomal membrane cholesterol dynamics. Biochemistry. 2000;39(26):7662–77.10869172 10.1021/bi992686h
40. Lim CY Davis OB Shin HR Zhang J Berdan CA Jiang X ER–lysosome contacts enable cholesterol sensing by mTORC1 and drive aberrant growth signalling in niemann-pick type C Nat Cell Biol 2019 21 10 1206 1218 10.1038/s41556-019-0391-5 31548609
Lim CY, Davis OB, Shin HR, Zhang J, Berdan CA, Jiang X, et al. ER–lysosome contacts enable cholesterol sensing by mTORC1 and drive aberrant growth signalling in niemann-pick type C. Nat Cell Biol. 2019;21(10):1206–18.31548609 10.1038/s41556-019-0391-5
41. Heybrock S Kanerva K Meng Y Ing C Liang A Xiong ZJ Lysosomal integral membrane protein-2 (LIMP-2/SCARB2) is involved in lysosomal cholesterol export Nat Commun 2019 10 1 3521 10.1038/s41467-019-11425-0 31387993
Heybrock S, Kanerva K, Meng Y, Ing C, Liang A, Xiong ZJ, et al. Lysosomal integral membrane protein-2 (LIMP-2/SCARB2) is involved in lysosomal cholesterol export. Nat Commun. 2019;10(1):3521.31387993 10.1038/s41467-019-11425-0
42. Jadot M Andrianaivo F Dubois F Wattiaux R Effects of methylcyclodextrin on lysosomes Eur J Biochem 2001 268 5 1392 1399 10.1046/j.1432-1327.2001.02006.x 11231291
Jadot M, Andrianaivo F, Dubois F, Wattiaux R. Effects of methylcyclodextrin on lysosomes. Eur J Biochem. 2001;268(5):1392–9.11231291 10.1046/j.1432-1327.2001.02006.x
43. Appelqvist H Nilsson C Garner B Brown AJ Kågedal K Öllinger K Attenuation of the lysosomal death pathway by lysosomal cholesterol accumulation Am J Pathol 2011 178 2 629 639 10.1016/j.ajpath.2010.10.030 21281795
Appelqvist H, Nilsson C, Garner B, Brown AJ, Kågedal K, Öllinger K. Attenuation of the lysosomal death pathway by lysosomal cholesterol accumulation. Am J Pathol. 2011;178(2):629–39.21281795 10.1016/j.ajpath.2010.10.030
44. Appelqvist H Sandin L Björnström K Saftig P Garner B Öllinger K Sensitivity to lysosome-dependent cell death is directly regulated by lysosomal cholesterol content PLoS ONE 2012 7 11 1 11 10.1371/journal.pone.0050262
Appelqvist H, Sandin L, Björnström K, Saftig P, Garner B, Öllinger K, et al. Sensitivity to lysosome-dependent cell death is directly regulated by lysosomal cholesterol content. PLoS ONE. 2012;7(11):1–11.10.1371/journal.pone.0050262
45. Fouchier F Mego JL Dang JSC Thyroid lysosomes: the stability of the lysosomal membrane Eur J Cell Biol 1983 30 2 272 278 11596502
Fouchier F, Mego JL, Dang JSC. Thyroid lysosomes: the stability of the lysosomal membrane. Eur J Cell Biol. 1983;30(2):272–8.11596502
46. Boya P Kroemer G Lysosomal membrane permeabilization in cell death Oncogene 2008 27 50 6434 6451 10.1038/onc.2008.310 18955971
Boya P, Kroemer G. Lysosomal membrane permeabilization in cell death. Oncogene. 2008;27(50):6434–51.18955971 10.1038/onc.2008.310
47. Oberle C Huai J Reinheckel T Tacke M Rassner M Ekert PG Lysosomal membrane permeabilization and cathepsin release is a Bax/Bak-dependent, amplifying event of apoptosis in fibroblasts and monocytes Cell Death Differ 2010 17 7 1167 1178 10.1038/cdd.2009.214 20094062
Oberle C, Huai J, Reinheckel T, Tacke M, Rassner M, Ekert PG, et al. Lysosomal membrane permeabilization and cathepsin release is a Bax/Bak-dependent, amplifying event of apoptosis in fibroblasts and monocytes. Cell Death Differ. 2010;17(7):1167–78.20094062 10.1038/cdd.2009.214
48. Funk RS Krise JP Cationic amphiphilic drugs cause a marked expansion of apparent lysosomal volume: implications for an intracellular distribution-based drug interaction Mol Pharm 2012 9 5 1384 1395 10.1021/mp200641e 22449202
Funk RS, Krise JP. Cationic amphiphilic drugs cause a marked expansion of apparent lysosomal volume: implications for an intracellular distribution-based drug interaction. Mol Pharm. 2012;9(5):1384–95.22449202 10.1021/mp200641e
49. Boya P Lysosomal function and dysfunction: mechanism and disease Antioxid Redox Signal 2011 17 5 766 774 10.1089/ars.2011.4405
Boya P. Lysosomal function and dysfunction: mechanism and disease. Antioxid Redox Signal. 2011;17(5):766–74.10.1089/ars.2011.4405
50. Kågedal K Johansson AC Johansson U Heimlich G Roberg K Wang NS Lysosomal membrane permeabilization during apoptosis—involvement of bax? Int J Exp Pathol 2005 86 5 309 321 10.1111/j.0959-9673.2005.00442.x 16191103
Kågedal K, Johansson AC, Johansson U, Heimlich G, Roberg K, Wang NS, et al. Lysosomal membrane permeabilization during apoptosis—involvement of bax? Int J Exp Pathol. 2005;86(5):309–21.16191103 10.1111/j.0959-9673.2005.00442.x
51. Eriksson I Wäster P Öllinger K Restoration of lysosomal function after damage is accompanied by recycling of lysosomal membrane proteins Cell Death Dis 2020 10.1038/s41419-020-2527-8 32409651
Eriksson I, Wäster P, Öllinger K. Restoration of lysosomal function after damage is accompanied by recycling of lysosomal membrane proteins. Cell Death Dis. 2020. 10.1038/s41419-020-2527-8.32409651 10.1038/s41419-020-2527-8
52. Maejima I Takahashi A Omori H Kimura T Takabatake Y Saitoh T Autophagy sequesters damaged lysosomes to control lysosomal biogenesis and kidney injury EMBO J 2013 32 17 2336 2347 10.1038/emboj.2013.171 23921551
Maejima I, Takahashi A, Omori H, Kimura T, Takabatake Y, Saitoh T, et al. Autophagy sequesters damaged lysosomes to control lysosomal biogenesis and kidney injury. EMBO J. 2013;32(17):2336–47.23921551 10.1038/emboj.2013.171
53. Martins WK Costa ÉT Cruz MC Stolf BS Miotto R Cordeiro RM Parallel damage in mitochondrial and lysosomal compartments promotes efficient cell death with autophagy: the case of the pentacyclic triterpenoids Sci Rep 2015 5 June 1 17
Martins WK, Costa ÉT, Cruz MC, Stolf BS, Miotto R, Cordeiro RM, et al. Parallel damage in mitochondrial and lysosomal compartments promotes efficient cell death with autophagy: the case of the pentacyclic triterpenoids. Sci Rep. 2015;5(June):1–17.
54. Burbidge K Rademacher DJ Mattick J Zack S Grillini A Bousset L LGALS3 (galectin 3) mediates an unconventional secretion of SNCA/α-synuclein in response to lysosomal membrane damage by the autophagic-lysosomal pathway in human midbrain dopamine neurons Autophagy 2021 6 1 29
Burbidge K, Rademacher DJ, Mattick J, Zack S, Grillini A, Bousset L, et al. LGALS3 (galectin 3) mediates an unconventional secretion of SNCA/α-synuclein in response to lysosomal membrane damage by the autophagic-lysosomal pathway in human midbrain dopamine neurons. Autophagy. 2021;6:1–29.
55. Flavin WP Bousset L Green ZC Chu Y Skarpathiotis S Chaney MJ Endocytic vesicle rupture is a conserved mechanism of cellular invasion by amyloid proteins Acta Neuropathol 2017 134 4 629 653 10.1007/s00401-017-1722-x 28527044
Flavin WP, Bousset L, Green ZC, Chu Y, Skarpathiotis S, Chaney MJ, et al. Endocytic vesicle rupture is a conserved mechanism of cellular invasion by amyloid proteins. Acta Neuropathol. 2017;134(4):629–53.28527044 10.1007/s00401-017-1722-x
56. Jadot M Colmant C Wattiaux-De Coninck S Wattiaux R Intralysosomal hydrolysis of glycyl-L-phenylalanine 2-naphthylamide Biochem J 1984 219 3 965 970 10.1042/bj2190965 6743255
Jadot M, Colmant C, Wattiaux-De Coninck S, Wattiaux R. Intralysosomal hydrolysis of glycyl-L-phenylalanine 2-naphthylamide. Biochem J. 1984;219(3):965–70.6743255 10.1042/bj2190965
57. Barondes SH Cooper DN Gitt MA Leffler H Galectins. structure and function of a large family of animal lectins J Biol Chem 1994 269 33 20807 10 10.1016/S0021-9258(17)31891-4 8063692
Barondes SH, Cooper DN, Gitt MA, Leffler H. Galectins. structure and function of a large family of animal lectins. J Biol Chem. 1994;269(33):20807–10.8063692 10.1016/S0021-9258(17)31891-4
58. Haudek KC Spronk KJ Voss PG Patterson RJ Wang JLAE Dynamics of galectin-3 in the nucleus and cytoplasm Biochim Biophys Acta 2011 23 1 1 7
Haudek KC, Spronk KJ, Voss PG, Patterson RJ, Wang JLAE. Dynamics of galectin-3 in the nucleus and cytoplasm. Biochim Biophys Acta. 2011;23(1):1–7.
59. Popa SJ Stewart SE Moreau K Unconventional secretion of annexins and galectins Semin Cell Dev Biol 2018 83 42 50 10.1016/j.semcdb.2018.02.022 29501720
Popa SJ, Stewart SE, Moreau K. Unconventional secretion of annexins and galectins. Semin Cell Dev Biol. 2018;83:42–50.29501720 10.1016/j.semcdb.2018.02.022
60. Nabi IR Shankar J Dennis JW The galectin lattice at a glance J Cell Sci 2015 128 13 2213 2219 10.1242/jcs.151159 26092931
Nabi IR, Shankar J, Dennis JW. The galectin lattice at a glance. J Cell Sci. 2015;128(13):2213–9.26092931 10.1242/jcs.151159
61. Stegmayr J Zetterberg F Carlsson MC Huang X Sharma G Kahl-Knutson B Extracellular and intracellular small-molecule galectin-3 inhibitors Sci Rep 2019 9 1 1 12 10.1038/s41598-019-38497-8 30626917
Stegmayr J, Zetterberg F, Carlsson MC, Huang X, Sharma G, Kahl-Knutson B, et al. Extracellular and intracellular small-molecule galectin-3 inhibitors. Sci Rep. 2019;9(1):1–12.30626917 10.1038/s41598-019-38497-8
62. Camby I Le Mercier M Lefranc F Kiss R Galectin-1: a small protein with major functions Glycobiology 2006 10.1093/glycob/cwl025 16840800
Camby I, Le Mercier M, Lefranc F, Kiss R. Galectin-1: a small protein with major functions. Glycobiology. 2006. 10.1093/glycob/cwl025.16840800 10.1093/glycob/cwl025
63. Lindgreen A Lindgreen A Extracellular functions of galectin-3 Glycoconj J 2004 19 1 527 535
Lindgreen A, Lindgreen A. Extracellular functions of galectin-3. Glycoconj J. 2004;19(1):527–35.
64. Garner OB Baum LG Galectin-glycan lattices regulate cell-surface glycoprotein organization and signalling Biochem Soc Trans 2008 36 6 1472 1477 10.1042/BST0361472 19021578
Garner OB, Baum LG. Galectin-glycan lattices regulate cell-surface glycoprotein organization and signalling. Biochem Soc Trans. 2008;36(6):1472–7.19021578 10.1042/BST0361472
65. Weng IC Chen HL Lo TH Lin WH Chen HY Hsu DK Cytosolic galectin-3 and -8 regulate antibacterial autophagy through differential recognition of host glycans on damaged phagosomes Glycobiology 2018 28 6 392 405 10.1093/glycob/cwy017 29800364
Weng IC, Chen HL, Lo TH, Lin WH, Chen HY, Hsu DK, et al. Cytosolic galectin-3 and -8 regulate antibacterial autophagy through differential recognition of host glycans on damaged phagosomes. Glycobiology. 2018;28(6):392–405.29800364 10.1093/glycob/cwy017
66. Jia J Abudu YP Claude-Taupin A Gu Y Kumar S Choi SW Galectins control mTOR in response to endomembrane damage Mol Cell 2018 70 1 120 135.e8 10.1016/j.molcel.2018.03.009 29625033
Jia J, Abudu YP, Claude-Taupin A, Gu Y, Kumar S, Choi SW, et al. Galectins control mTOR in response to endomembrane damage. Mol Cell. 2018;70(1):120-135.e8.29625033 10.1016/j.molcel.2018.03.009
67. Aits S Kricker J Liu B Ellegaard AM Hämälistö S Tvingsholm S Sensitive detection of lysosomal membrane permeabilization by lysosomal galectin puncta assay Autophagy 2015 11 8 1408 24 10.1080/15548627.2015.1063871 26114578
Aits S, Kricker J, Liu B, Ellegaard AM, Hämälistö S, Tvingsholm S, et al. Sensitive detection of lysosomal membrane permeabilization by lysosomal galectin puncta assay. Autophagy. 2015;11(8):1408–24.26114578 10.1080/15548627.2015.1063871
68. Radulovic M Schink KO Wenzel EM Lafont F Stenmark H Nähse V ESCRT-mediated lysosome repair precedes lysophagy and promotes cell survival EMBO J 2018 37 21 e99753 10.15252/embj.201899753 30314966
Radulovic M, Schink KO, Wenzel EM, Lafont F, Stenmark H, Nähse V, et al. ESCRT-mediated lysosome repair precedes lysophagy and promotes cell survival. EMBO J. 2018;37(21):e99753.30314966 10.15252/embj.201899753
69. Jia J Claude-Taupin A Gu Y Choi SW Peters R Bissa B Galectin-3 coordinates a cellular system for lysosomal repair and removal Dev Cell 2020 52 1 69 87.e8 10.1016/j.devcel.2019.10.025 31813797
Jia J, Claude-Taupin A, Gu Y, Choi SW, Peters R, Bissa B, et al. Galectin-3 coordinates a cellular system for lysosomal repair and removal. Dev Cell. 2020;52(1):69-87.e8.31813797 10.1016/j.devcel.2019.10.025
70. Skowyra ML Schlesinger PH Naismith TV Hanson PI Triggered recruitment of ESCRT machinery promotes endolysosomal repair Science 2018 360 6384 eaar5078 10.1126/science.aar5078 29622626
Skowyra ML, Schlesinger PH, Naismith TV, Hanson PI. Triggered recruitment of ESCRT machinery promotes endolysosomal repair. Science. 2018;360(6384):eaar5078.29622626 10.1126/science.aar5078
71. Eguchi T Kuwahara T Sakurai M Komori T Fujimoto T Ito G LRRK2 and its substrate Rab GTPases are sequentially targeted onto stressed lysosomes and maintain their homeostasis Proc Natl Acad Sci U S A 2018 115 39 E9115 E9124 10.1073/pnas.1812196115 30209220
Eguchi T, Kuwahara T, Sakurai M, Komori T, Fujimoto T, Ito G, et al. LRRK2 and its substrate Rab GTPases are sequentially targeted onto stressed lysosomes and maintain their homeostasis. Proc Natl Acad Sci U S A. 2018;115(39):E9115–24.30209220 10.1073/pnas.1812196115
72. Kuwahara T Funakawa K Komori T Sakurai M Yoshii G Eguchi T Roles of lysosomotropic agents on LRRK2 activation and Rab10 phosphorylation Neurobiol Dis 2020 145 May 105081 10.1016/j.nbd.2020.105081 32919031
Kuwahara T, Funakawa K, Komori T, Sakurai M, Yoshii G, Eguchi T, et al. Roles of lysosomotropic agents on LRRK2 activation and Rab10 phosphorylation. Neurobiol Dis. 2020;145(May): 105081.32919031 10.1016/j.nbd.2020.105081
73. Bonet-Ponce L Beilina A Williamson CD Lindberg E Kluss JH Saez-Atienzar S LRRK2 mediates tubulation and vesicle sorting from lysosomes Sci Adv 2022 6 46 eabb2454 10.1126/sciadv.abb2454
Bonet-Ponce L, Beilina A, Williamson CD, Lindberg E, Kluss JH, Saez-Atienzar S, et al. LRRK2 mediates tubulation and vesicle sorting from lysosomes. Sci Adv. 2022;6(46):eabb2454.10.1126/sciadv.abb2454
74. Kluss JH Bonet-Ponce L Lewis PA Cookson MR Directing LRRK2 to membranes of the endolysosomal pathway triggers RAB phosphorylation and JIP4 recruitment Neurobiol Dis 2022 170 April 105769 10.1016/j.nbd.2022.105769 35580815
Kluss JH, Bonet-Ponce L, Lewis PA, Cookson MR. Directing LRRK2 to membranes of the endolysosomal pathway triggers RAB phosphorylation and JIP4 recruitment. Neurobiol Dis. 2022;170(April): 105769.35580815 10.1016/j.nbd.2022.105769
75. Goul CS Zoncu R PITTching in for lysosome repair Dev Cell 2022 57 20 2347 2349 10.1016/j.devcel.2022.09.014 36283389
Goul CS, Zoncu R. PITTching in for lysosome repair. Dev Cell. 2022;57(20):2347–9.36283389 10.1016/j.devcel.2022.09.014
76. Tan JX Finkel T A phosphoinositide signalling pathway mediates rapid lysosomal repair Nature 2022 609 7928 815 821 10.1038/s41586-022-05164-4 36071159
Tan JX, Finkel T. A phosphoinositide signalling pathway mediates rapid lysosomal repair. Nature. 2022;609(7928):815–21.36071159 10.1038/s41586-022-05164-4
77. Niekamp P Scharte F Sokoya T Vittadello L Kim Y Deng Y Ca2+-activated sphingomyelin scrambling and turnover mediate ESCRT-independent lysosomal repair Nat Commun 2022 10.1038/s41467-022-29481-4 35388011
Niekamp P, Scharte F, Sokoya T, Vittadello L, Kim Y, Deng Y, et al. Ca2+-activated sphingomyelin scrambling and turnover mediate ESCRT-independent lysosomal repair. Nat Commun. 2022. 10.1038/s41467-022-29481-4.35388011 10.1038/s41467-022-29481-4
78. Shin HR Zoncu R Finding sugar in the pantry: how galectins detect and signal lysosomal damage Mol Cell 2018 70 1 5 7 10.1016/j.molcel.2018.03.017 29625038
Shin HR, Zoncu R. Finding sugar in the pantry: how galectins detect and signal lysosomal damage. Mol Cell. 2018;70(1):5–7.29625038 10.1016/j.molcel.2018.03.017
79. Jia J Bissa B Brecht L Allers L Choi SW Gu Y AMPK, a regulator of metabolism and autophagy, is activated by lysosomal damage via a novel galectin-directed ubiquitin signal transduction system Mol Cell 2020 77 5 951 969.e9 10.1016/j.molcel.2019.12.028 31995728
Jia J, Bissa B, Brecht L, Allers L, Choi SW, Gu Y, et al. AMPK, a regulator of metabolism and autophagy, is activated by lysosomal damage via a novel galectin-directed ubiquitin signal transduction system. Mol Cell. 2020;77(5):951-969.e9.31995728 10.1016/j.molcel.2019.12.028
80. Chauhan S Kumar S Jain A Ponpuak M Mudd MH Kimura T TRIMs and galectins globally cooperate and TRIM16 and galectin-3 co-direct autophagy in endomembrane damage homeostasis Dev Cell 2016 39 1 13 27 10.1016/j.devcel.2016.08.003 27693506
Chauhan S, Kumar S, Jain A, Ponpuak M, Mudd MH, Kimura T, et al. TRIMs and galectins globally cooperate and TRIM16 and galectin-3 co-direct autophagy in endomembrane damage homeostasis. Dev Cell. 2016;39(1):13–27.27693506 10.1016/j.devcel.2016.08.003
81. Yoshida Y Yasuda S Fujita T Hamasaki M Murakami A Kawawaki J Ubiquitination of exposed glycoproteins by SCFFBXO27 directs damaged lysosomes for autophagy Proc Natl Acad Sci U S A 2017 114 32 8574 8579 10.1073/pnas.1702615114 28743755
Yoshida Y, Yasuda S, Fujita T, Hamasaki M, Murakami A, Kawawaki J, et al. Ubiquitination of exposed glycoproteins by SCFFBXO27 directs damaged lysosomes for autophagy. Proc Natl Acad Sci U S A. 2017;114(32):8574–9.28743755 10.1073/pnas.1702615114
82. Gahlot P Kravic B Rota G van den Boom J Levantovsky S Schulze N Lysosomal damage sensing and lysophagy initiation by SPG20-ITCH Mol Cell 2024 10.1016/j.molcel.2024.02.029 38503285
Gahlot P, Kravic B, Rota G, van den Boom J, Levantovsky S, Schulze N, et al. Lysosomal damage sensing and lysophagy initiation by SPG20-ITCH. Mol Cell. 2024. 10.1016/j.molcel.2024.02.029.38503285 10.1016/j.molcel.2024.02.029
83. Papadopoulos C Kirchner P Bug M Grum D Koerver L Schulze N VCP/p97 cooperates with YOD1, UBXD1 and PLAA to drive clearance of ruptured lysosomes by autophagy EMBO J 2017 36 2 135 150 10.15252/embj.201695148 27753622
Papadopoulos C, Kirchner P, Bug M, Grum D, Koerver L, Schulze N, et al. VCP/p97 cooperates with YOD1, UBXD1 and PLAA to drive clearance of ruptured lysosomes by autophagy. EMBO J. 2017;36(2):135–50.27753622 10.15252/embj.201695148
84. Koerver L Papadopoulos C Liu B Kravic B Rota G Brecht L The ubiquitin-conjugating enzyme UBE2QL1 coordinates lysophagy in response to endolysosomal damage EMBO Rep 2019 20 10 e48014 10.15252/embr.201948014 31432621
Koerver L, Papadopoulos C, Liu B, Kravic B, Rota G, Brecht L, et al. The ubiquitin-conjugating enzyme UBE2QL1 coordinates lysophagy in response to endolysosomal damage. EMBO Rep. 2019;20(10): e48014.31432621 10.15252/embr.201948014
85. Teranishi H Tabata K Saeki M Umemoto T Hatta T Otomo T Identification of CUL4A-DDB1-WDFY1 as an E3 ubiquitin ligase complex involved in initiation of lysophagy Cell Rep 2022 40 11 111349 10.1016/j.celrep.2022.111349 36103833
Teranishi H, Tabata K, Saeki M, Umemoto T, Hatta T, Otomo T, et al. Identification of CUL4A-DDB1-WDFY1 as an E3 ubiquitin ligase complex involved in initiation of lysophagy. Cell Rep. 2022;40(11): 111349.36103833 10.1016/j.celrep.2022.111349
86. Kravić B Bionda T Siebert A Gahlot P Levantovsky S Behrends C Ubiquitin profiling of lysophagy identifies actin stabilizer CNN2 as a target of VCP/p97 and uncovers a link to HSPB1 Mol Cell 2022 82 14 2633 2649.e7 10.1016/j.molcel.2022.06.012 35793674
Kravić B, Bionda T, Siebert A, Gahlot P, Levantovsky S, Behrends C, et al. Ubiquitin profiling of lysophagy identifies actin stabilizer CNN2 as a target of VCP/p97 and uncovers a link to HSPB1. Mol Cell. 2022;82(14):2633-2649.e7.35793674 10.1016/j.molcel.2022.06.012
87. Papadopoulos C Kirchner P Bug M Grum D Koerver L Schulze N VCP/p97 cooperates with YOD1, UBXD1 and PLAA to drive clearance of ruptured lysosomes by autophagy EMBO J 2017 36 2 135 150 10.15252/embj.201695148 27753622
Papadopoulos C, Kirchner P, Bug M, Grum D, Koerver L, Schulze N, et al. VCP/p97 cooperates with YOD1, UBXD1 and PLAA to drive clearance of ruptured lysosomes by autophagy. EMBO J. 2017;36(2):135–50.27753622 10.15252/embj.201695148
88. Richter B Sliter DA Herhaus L Stolz A Wang C Beli P Phosphorylation of OPTN by TBK1 enhances its binding to Ub chains and promotes selective autophagy of damaged mitochondria Proc Natl Acad Sci 2016 113 15 4039 4044 10.1073/pnas.1523926113 27035970
Richter B, Sliter DA, Herhaus L, Stolz A, Wang C, Beli P, et al. Phosphorylation of OPTN by TBK1 enhances its binding to Ub chains and promotes selective autophagy of damaged mitochondria. Proc Natl Acad Sci. 2016;113(15):4039–44.27035970 10.1073/pnas.1523926113
89. Thurston TLM Ryzhakov G Bloor S von Muhlinen N Randow F The TBK1 adaptor and autophagy receptor NDP52 restricts the proliferation of ubiquitin-coated bacteria Nat Immunol 2009 10 11 1215 1221 10.1038/ni.1800 19820708
Thurston TLM, Ryzhakov G, Bloor S, von Muhlinen N, Randow F. The TBK1 adaptor and autophagy receptor NDP52 restricts the proliferation of ubiquitin-coated bacteria. Nat Immunol. 2009;10(11):1215–21.19820708 10.1038/ni.1800
90. Gallagher ER Holzbaur ELF The selective autophagy adaptor p62/SQSTM1 forms phase condensates regulated by HSP27 that facilitate the clearance of damaged lysosomes via lysophagy Cell Rep 2023 42 2 112037 10.1016/j.celrep.2023.112037 36701233
Gallagher ER, Holzbaur ELF. The selective autophagy adaptor p62/SQSTM1 forms phase condensates regulated by HSP27 that facilitate the clearance of damaged lysosomes via lysophagy. Cell Rep. 2023;42(2): 112037.36701233 10.1016/j.celrep.2023.112037
91. Corkery DP Castro-Gonzalez S Knyazeva A Herzog LK Wu Y-W An ATG12-ATG5-TECPR1 E3-like complex regulates unconventional LC3 lipidation at damaged lysosomes EMBO Rep 2023 24 9 e56841 10.15252/embr.202356841 37381828
Corkery DP, Castro-Gonzalez S, Knyazeva A, Herzog LK, Wu Y-W. An ATG12-ATG5-TECPR1 E3-like complex regulates unconventional LC3 lipidation at damaged lysosomes. EMBO Rep. 2023;24(9): e56841.37381828 10.15252/embr.202356841
92. Cross J Durgan J McEwan DG Tayler M Ryan KM Florey O Lysosome damage triggers direct ATG8 conjugation and ATG2 engagement via non-canonical autophagy J Cell Biol 2023 222 12 e202303078 10.1083/jcb.202303078 37796195
Cross J, Durgan J, McEwan DG, Tayler M, Ryan KM, Florey O. Lysosome damage triggers direct ATG8 conjugation and ATG2 engagement via non-canonical autophagy. J Cell Biol. 2023;222(12): e202303078.37796195 10.1083/jcb.202303078
93. Hooper KM Jacquin E Li T Goodwin JM Brumell JH Durgan J V-ATPase is a universal regulator of LC3-associated phagocytosis and non-canonical autophagy J Cell Biol 2022 221 6 e202105112 10.1083/jcb.202105112 35511089
Hooper KM, Jacquin E, Li T, Goodwin JM, Brumell JH, Durgan J, et al. V-ATPase is a universal regulator of LC3-associated phagocytosis and non-canonical autophagy. J Cell Biol. 2022;221(6): e202105112.35511089 10.1083/jcb.202105112
94. Raben N Puertollano R TFEB and TFE3: linking lysosomes to cellular adaptation to stress Annu Rev Cell Dev Biol 2016 32 1 255 278 10.1146/annurev-cellbio-111315-125407 27298091
Raben N, Puertollano R. TFEB and TFE3: linking lysosomes to cellular adaptation to stress. Annu Rev Cell Dev Biol. 2016;32(1):255–78.27298091 10.1146/annurev-cellbio-111315-125407
95. Medina DL Fraldi A Bouche V Annunziata F Mansueto G Spampanato C Transcriptional activation of lysosomal exocytosis promotes cellular clearance Dev Cell 2011 21 3 421 430 10.1016/j.devcel.2011.07.016 21889421
Medina DL, Fraldi A, Bouche V, Annunziata F, Mansueto G, Spampanato C, et al. Transcriptional activation of lysosomal exocytosis promotes cellular clearance. Dev Cell. 2011;21(3):421–30.21889421 10.1016/j.devcel.2011.07.016
96. Martina JA Diab HI Lishu L Jeong LA Patange S Raben N The nutrient-responsive transcription factor TFE3 promotes autophagy, lysosomal biogenesis, and clearance of cellular debris Sci Signal 2014 7 309 ra9 10.1126/scisignal.2004754 24448649
Martina JA, Diab HI, Lishu L, Jeong LA, Patange S, Raben N, et al. The nutrient-responsive transcription factor TFE3 promotes autophagy, lysosomal biogenesis, and clearance of cellular debris. Sci Signal. 2014;7(309):ra9.24448649 10.1126/scisignal.2004754
97. Sardiello M Palmieri M di Ronza A Medina DL Valenza M Gennarino VA A gene network regulating lysosomal biogenesis and function Science 2009 325 5939 473 477 10.1126/science.1174447 19556463
Sardiello M, Palmieri M, di Ronza A, Medina DL, Valenza M, Gennarino VA, et al. A gene network regulating lysosomal biogenesis and function. Science. 2009;325(5939):473–7.19556463 10.1126/science.1174447
98. Cui Z Napolitano G de Araujo MEG Esposito A Monfregola J Huber LA Structure of the lysosomal mTORC1–TFEB–Rag–ragulator megacomplex Nature 2023 614 7948 572 579 10.1038/s41586-022-05652-7 36697823
Cui Z, Napolitano G, de Araujo MEG, Esposito A, Monfregola J, Huber LA, et al. Structure of the lysosomal mTORC1–TFEB–Rag–ragulator megacomplex. Nature. 2023;614(7948):572–9.36697823 10.1038/s41586-022-05652-7
99. Medina DL Di Paola S Peluso I Armani A De Stefani D Venditti R Lysosomal calcium signalling regulates autophagy through calcineurin and TFEB Nat Cell Biol 2015 17 3 288 299 10.1038/ncb3114 25720963
Medina DL, Di Paola S, Peluso I, Armani A, De Stefani D, Venditti R, et al. Lysosomal calcium signalling regulates autophagy through calcineurin and TFEB. Nat Cell Biol. 2015;17(3):288–99.25720963 10.1038/ncb3114
100. Ferron M Settembre C Shimazu J Lacombe J Kato S Rawlings DJ A RANKL–PKCβ–TFEB signaling cascade is necessary for lysosomal biogenesis in osteoclasts Genes Dev 2013 27 8 955 969 10.1101/gad.213827.113 23599343
Ferron M, Settembre C, Shimazu J, Lacombe J, Kato S, Rawlings DJ, et al. A RANKL–PKCβ–TFEB signaling cascade is necessary for lysosomal biogenesis in osteoclasts. Genes Dev. 2013;27(8):955–69.23599343 10.1101/gad.213827.113
101. Xu Y Ren J He X Chen H Wei T Feng W YWHA/14-3-3 proteins recognize phosphorylated TFEB by a noncanonical mode for controlling TFEB cytoplasmic localization Autophagy 2019 15 6 1017 1030 10.1080/15548627.2019.1569928 30653408
Xu Y, Ren J, He X, Chen H, Wei T, Feng W. YWHA/14-3-3 proteins recognize phosphorylated TFEB by a noncanonical mode for controlling TFEB cytoplasmic localization. Autophagy. 2019;15(6):1017–30.30653408 10.1080/15548627.2019.1569928
102. Martina JA Chen Y Gucek M Puertollano R MTORC1 functions as a transcriptional regulator of autophagy by preventing nuclear transport of TFEB Autophagy 2012 8 6 903 914 10.4161/auto.19653 22576015
Martina JA, Chen Y, Gucek M, Puertollano R. MTORC1 functions as a transcriptional regulator of autophagy by preventing nuclear transport of TFEB. Autophagy. 2012;8(6):903–14.22576015 10.4161/auto.19653
103. Settembre C Zoncu R Medina DL Vetrini F Erdin S Erdin S A lysosome-to-nucleus signalling mechanism senses and regulates the lysosome via mTOR and TFEB EMBO J 2012 31 5 1095 1108 10.1038/emboj.2012.32 22343943
Settembre C, Zoncu R, Medina DL, Vetrini F, Erdin S, Erdin S, et al. A lysosome-to-nucleus signalling mechanism senses and regulates the lysosome via mTOR and TFEB. EMBO J. 2012;31(5):1095–108.22343943 10.1038/emboj.2012.32
104. Martina JA Puertollano R Rag GTPases mediate amino acid–dependent recruitment of TFEB and MITF to lysosomes J Cell Biol 2013 200 4 475 491 10.1083/jcb.201209135 23401004
Martina JA, Puertollano R. Rag GTPases mediate amino acid–dependent recruitment of TFEB and MITF to lysosomes. J Cell Biol. 2013;200(4):475–91.23401004 10.1083/jcb.201209135
105. Silvestrini MJ Johnson JR Kumar AV Thakurta TG Blais K Neill ZA Nuclear export inhibition enhances HLH-30/TFEB activity, autophagy, and lifespan Cell Rep 2018 23 7 1915 1921 10.1016/j.celrep.2018.04.063 29768192
Silvestrini MJ, Johnson JR, Kumar AV, Thakurta TG, Blais K, Neill ZA, et al. Nuclear export inhibition enhances HLH-30/TFEB activity, autophagy, and lifespan. Cell Rep. 2018;23(7):1915–21.29768192 10.1016/j.celrep.2018.04.063
106. Napolitano G Esposito A Choi H Matarese M Benedetti V Di Malta C mTOR-dependent phosphorylation controls TFEB nuclear export Nat Commun 2018 9 1 3312 10.1038/s41467-018-05862-6 30120233
Napolitano G, Esposito A, Choi H, Matarese M, Benedetti V, Di Malta C, et al. mTOR-dependent phosphorylation controls TFEB nuclear export. Nat Commun. 2018;9(1):3312.30120233 10.1038/s41467-018-05862-6
107. Zhang J Wang J Zhou Z Park J-E Wang L Wu S Importance of TFEB acetylation in control of its transcriptional activity and lysosomal function in response to histone deacetylase inhibitors Autophagy 2018 14 6 1043 1059 30059277
Zhang J, Wang J, Zhou Z, Park J-E, Wang L, Wu S, et al. Importance of TFEB acetylation in control of its transcriptional activity and lysosomal function in response to histone deacetylase inhibitors. Autophagy. 2018;14(6):1043–59.30059277
108. Li T Yin L Kang X Xue W Wang N Zhang J TFEB acetylation promotes lysosome biogenesis and ameliorates Alzheimer’s disease–relevant phenotypes in mice J Biol Chem 2022 298 12 102649 10.1016/j.jbc.2022.102649 36441024
Li T, Yin L, Kang X, Xue W, Wang N, Zhang J, et al. TFEB acetylation promotes lysosome biogenesis and ameliorates Alzheimer’s disease–relevant phenotypes in mice. J Biol Chem. 2022;298(12): 102649.36441024 10.1016/j.jbc.2022.102649
109. Ong AJS Bladen CE Tigani TA Karamalakis AP Evason KJ Brown KK The KEAP1–NRF2 pathway regulates TFEB/TFE3-dependent lysosomal biogenesis Proc Natl Acad Sci 2023 120 22 e2217425120 10.1073/pnas.2217425120 37216554
Ong AJS, Bladen CE, Tigani TA, Karamalakis AP, Evason KJ, Brown KK, et al. The KEAP1–NRF2 pathway regulates TFEB/TFE3-dependent lysosomal biogenesis. Proc Natl Acad Sci. 2023;120(22): e2217425120.37216554 10.1073/pnas.2217425120
110. Chen D Wang Z Zhao YG Zheng H Zhao H Liu N Inositol polyphosphate multikinase inhibits liquid-liquid phase separation of TFEB to negatively regulate autophagy activity Dev Cell 2020 55 5 588 602.e7 10.1016/j.devcel.2020.10.010 33290695
Chen D, Wang Z, Zhao YG, Zheng H, Zhao H, Liu N, et al. Inositol polyphosphate multikinase inhibits liquid-liquid phase separation of TFEB to negatively regulate autophagy activity. Dev Cell. 2020;55(5):588-602.e7.33290695 10.1016/j.devcel.2020.10.010
111. Wang Z Chen D Guan D Liang X Xue J Zhao H Material properties of phase-separated TFEB condensates regulate the autophagy-lysosome pathway J Cell Biol 2022 221 5 e202112024 10.1083/jcb.202112024 35293953
Wang Z, Chen D, Guan D, Liang X, Xue J, Zhao H, et al. Material properties of phase-separated TFEB condensates regulate the autophagy-lysosome pathway. J Cell Biol. 2022;221(5): e202112024.35293953 10.1083/jcb.202112024
112. Chauhan S Kumar S Jain A Ponpuak M Mudd MH Kimura T TRIMs and galectins globally cooperate and TRIM16 and galectin-3 co-direct autophagy in endomembrane damage homeostasis Dev Cell 2016 39 1 13 27 10.1016/j.devcel.2016.08.003 27693506
Chauhan S, Kumar S, Jain A, Ponpuak M, Mudd MH, Kimura T, et al. TRIMs and galectins globally cooperate and TRIM16 and galectin-3 co-direct autophagy in endomembrane damage homeostasis. Dev Cell. 2016;39(1):13–27.27693506 10.1016/j.devcel.2016.08.003
113. Leow SM Serene Chua SX Venkatachalam G Shen L Luo L Clement MV Sub-lethal oxidative stress induces lysosome biogenesis via a lysosomal membrane permeabilization-cathepsin-caspase 3-transcription factor EB-dependent pathway Oncotarget 2016 8 10 16170 10.18632/oncotarget.14016
Leow SM, Serene Chua SX, Venkatachalam G, Shen L, Luo L, Clement MV. Sub-lethal oxidative stress induces lysosome biogenesis via a lysosomal membrane permeabilization-cathepsin-caspase 3-transcription factor EB-dependent pathway. Oncotarget. 2016;8(10):16170.10.18632/oncotarget.14016
114. Nakamura S Shigeyama S Minami S Shima T Akayama S Matsuda T LC3 lipidation is essential for TFEB activation during the lysosomal damage response to kidney injury Nat Cell Biol 2020 22 10 1252 1263 10.1038/s41556-020-00583-9 32989250
Nakamura S, Shigeyama S, Minami S, Shima T, Akayama S, Matsuda T, et al. LC3 lipidation is essential for TFEB activation during the lysosomal damage response to kidney injury. Nat Cell Biol. 2020;22(10):1252–63.32989250 10.1038/s41556-020-00583-9
115. Xia Q Zheng H Li Y Xu W Wu C Xu J SMURF1 controls the PPP3/calcineurin complex and TFEB at a regulatory node for lysosomal biogenesis Autophagy 2023 20 4 1 17 37848407
Xia Q, Zheng H, Li Y, Xu W, Wu C, Xu J, et al. SMURF1 controls the PPP3/calcineurin complex and TFEB at a regulatory node for lysosomal biogenesis. Autophagy. 2023;20(4):1–17.37848407
116. Reddy A Caler EV Andrews NW Plasma membrane repair is mediated by Ca2+-regulated exocytosis of lysosomes Cell 2001 106 2 157 169 10.1016/S0092-8674(01)00421-4 11511344
Reddy A, Caler EV, Andrews NW. Plasma membrane repair is mediated by Ca2+-regulated exocytosis of lysosomes. Cell. 2001;106(2):157–69.11511344 10.1016/S0092-8674(01)00421-4
117. Castro-Gomes T Corrotte M Tam C Andrews NW Plasma membrane repair is regulated extracellularly by proteases released from lysosomes PLoS ONE 2016 11 3 e0152583 10.1371/journal.pone.0152583 27028538
Castro-Gomes T, Corrotte M, Tam C, Andrews NW. Plasma membrane repair is regulated extracellularly by proteases released from lysosomes. PLoS ONE. 2016;11(3): e0152583.27028538 10.1371/journal.pone.0152583
118. Andrews NW Regulated secretion of conventional lysosomes Trend Cell Biol 2000 10 8 316 321 10.1016/S0962-8924(00)01794-3
Andrews NW. Regulated secretion of conventional lysosomes. Trend Cell Biol. 2000;10(8):316–21.10.1016/S0962-8924(00)01794-3
119. Lachuer H Le L Lévêque-Fort S Goud B Schauer K Spatial organization of lysosomal exocytosis relies on membrane tension gradients Proc Natl Acad Sci 2023 120 8 e2207425120 10.1073/pnas.2207425120 36800388
Lachuer H, Le L, Lévêque-Fort S, Goud B, Schauer K. Spatial organization of lysosomal exocytosis relies on membrane tension gradients. Proc Natl Acad Sci. 2023;120(8): e2207425120.36800388 10.1073/pnas.2207425120
120. Arantes RME Andrews NW A role for synaptotagmin VII-regulated exocytosis of lysosomes in neurite outgrowth from primary sympathetic neurons J Neurosci 2006 26 17 4630 4637 10.1523/JNEUROSCI.0009-06.2006 16641243
Arantes RME, Andrews NW. A role for synaptotagmin VII-regulated exocytosis of lysosomes in neurite outgrowth from primary sympathetic neurons. J Neurosci. 2006;26(17):4630–7.16641243 10.1523/JNEUROSCI.0009-06.2006
121. Chen G Zhang Z Wei Z Cheng Q Li X Li W Lysosomal exocytosis in Schwann cells contributes to axon remyelination Glia 2012 60 2 295 305 10.1002/glia.21263 22042600
Chen G, Zhang Z, Wei Z, Cheng Q, Li X, Li W, et al. Lysosomal exocytosis in Schwann cells contributes to axon remyelination. Glia. 2012;60(2):295–305.22042600 10.1002/glia.21263
122. Grochowska KM Sperveslage M Raman R Failla AV Głów D Schulze C Chaperone-mediated autophagy in neuronal dendrites utilizes activity-dependent lysosomal exocytosis for protein disposal Cell Rep 2023 42 8 112998 10.1016/j.celrep.2023.112998 37590146
Grochowska KM, Sperveslage M, Raman R, Failla AV, Głów D, Schulze C, et al. Chaperone-mediated autophagy in neuronal dendrites utilizes activity-dependent lysosomal exocytosis for protein disposal. Cell Rep. 2023;42(8):112998.37590146 10.1016/j.celrep.2023.112998
123. Tsunemi T Perez-Rosello T Ishiguro Y Yoroisaka A Jeon S Hamada K Increased lysosomal exocytosis induced by lysosomal Ca2+ channel agonists protects human dopaminergic neurons from α-synuclein toxicity J Neurosci 2019 39 29 5760 5772 10.1523/JNEUROSCI.3085-18.2019 31097622
Tsunemi T, Perez-Rosello T, Ishiguro Y, Yoroisaka A, Jeon S, Hamada K, et al. Increased lysosomal exocytosis induced by lysosomal Ca2+ channel agonists protects human dopaminergic neurons from α-synuclein toxicity. J Neurosci. 2019;39(29):5760–72.31097622 10.1523/JNEUROSCI.3085-18.2019
124. Yu L Mcphee CK Zheng L Mardones GA Rong Y Peng J Termination of autophagy and reformation of lysosomes regulated by mTOR Nature 2010 10.1038/nature09076 21124459
Yu L, Mcphee CK, Zheng L, Mardones GA, Rong Y, Peng J, et al. Termination of autophagy and reformation of lysosomes regulated by mTOR. Nature. 2010. 10.1038/nature09076.21124459 10.1038/nature09076
125. Sun X Yang Y Zhong XZ Cao Q Zhu X-H Zhu X A negative feedback regulation of MTORC1 activity by the lysosomal Ca2+ channel MCOLN1 (mucolipin 1) using a CALM (calmodulin)-dependent mechanism Autophagy 2018 14 1 38 52 10.1080/15548627.2017.1389822 29460684
Sun X, Yang Y, Zhong XZ, Cao Q, Zhu X-H, Zhu X, et al. A negative feedback regulation of MTORC1 activity by the lysosomal Ca2+ channel MCOLN1 (mucolipin 1) using a CALM (calmodulin)-dependent mechanism. Autophagy. 2018;14(1):38–52.29460684 10.1080/15548627.2017.1389822
126. Rong Y Liu M Ma L Du W Zhang H Tian Y Clathrin and phosphatidylinositol-4,5-bisphosphate regulate autophagic lysosome reformation Nat Cell Biol 2012 14 9 924 934 10.1038/ncb2557 22885770
Rong Y, Liu M, Ma L, Du W, Zhang H, Tian Y, et al. Clathrin and phosphatidylinositol-4,5-bisphosphate regulate autophagic lysosome reformation. Nat Cell Biol. 2012;14(9):924–34.22885770 10.1038/ncb2557
127. Du W Su QP Chen Y Zhu Y Jiang D Rong Y Kinesin 1 drives autolysosome tubulation Dev Cell 2016 37 4 326 336 10.1016/j.devcel.2016.04.014 27219061
Du W, Su QP, Chen Y, Zhu Y, Jiang D, Rong Y, et al. Kinesin 1 drives autolysosome tubulation. Dev Cell. 2016;37(4):326–36.27219061 10.1016/j.devcel.2016.04.014
128. Bhattacharya A Mukherjee R Kuncha SK Brunstein ME Rathore R Junek S A lysosome membrane regeneration pathway depends on TBC1D15 and autophagic lysosomal reformation proteins Nat Cell Biol 2023 25 5 685 98 10.1038/s41556-023-01125-9 37024685
Bhattacharya A, Mukherjee R, Kuncha SK, Brunstein ME, Rathore R, Junek S, et al. A lysosome membrane regeneration pathway depends on TBC1D15 and autophagic lysosomal reformation proteins. Nat Cell Biol. 2023;25(5):685–98.37024685 10.1038/s41556-023-01125-9
129. Bright NA Reaves BJ Mullock BM Luzio JP Dense core lysosomes can fuse with late endosomes and are re-formed from the resultant hybrid organelles J Cell Sci 1997 110 17 2027 2040 10.1242/jcs.110.17.2027 9378754
Bright NA, Reaves BJ, Mullock BM, Luzio JP. Dense core lysosomes can fuse with late endosomes and are re-formed from the resultant hybrid organelles. J Cell Sci. 1997;110(17):2027–40.9378754 10.1242/jcs.110.17.2027
130. Bissig C Hurbain I Raposo G van Niel G PIKfyve activity regulates reformation of terminal storage lysosomes from endolysosomes Traffic 2017 18 11 747 757 10.1111/tra.12525 28857423
Bissig C, Hurbain I, Raposo G, van Niel G. PIKfyve activity regulates reformation of terminal storage lysosomes from endolysosomes. Traffic. 2017;18(11):747–57.28857423 10.1111/tra.12525
131. Sava I Davis LJ Gray SR Bright NA Luzio JP Reversible assembly and disassembly of V-ATPase during the lysosome regeneration cycle Mol Biol Cell 2024 35 5 ar63 10.1091/mbc.E23-08-0322 38446621
Sava I, Davis LJ, Gray SR, Bright NA, Luzio JP. Reversible assembly and disassembly of V-ATPase during the lysosome regeneration cycle. Mol Biol Cell. 2024;35(5):ar63.38446621 10.1091/mbc.E23-08-0322
132. Luzio JP Gray SR Bright NA Endosome–lysosome fusion Biochem Soc Trans 2010 38 6 1413 1416 10.1042/BST0381413 21118098
Luzio JP, Gray SR, Bright NA. Endosome–lysosome fusion. Biochem Soc Trans. 2010;38(6):1413–6.21118098 10.1042/BST0381413
133. Duclos S Corsini R Desjardins M Remodeling of endosomes during lysosome biogenesis involves `kiss and run’ fusion events regulated by rab5 J Cell Sci 2003 116 5 907 918 10.1242/jcs.00259 12571288
Duclos S, Corsini R, Desjardins M. Remodeling of endosomes during lysosome biogenesis involves `kiss and run’ fusion events regulated by rab5. J Cell Sci. 2003;116(5):907–18.12571288 10.1242/jcs.00259
134. Lim KH Diverse misfolded conformational strains and cross-seeding of misfolded proteins implicated in neurodegenerative diseases Front Mol Neurosci 2019 12 158 10.3389/fnmol.2019.00158 31338019
Lim KH. Diverse misfolded conformational strains and cross-seeding of misfolded proteins implicated in neurodegenerative diseases. Front Mol Neurosci. 2019;12:158.31338019 10.3389/fnmol.2019.00158
135. Goedert M Eisenberg DS Crowther RA Propagation of tau aggregates and neurodegeneration Annu Rev Neurosci 2017 40 1 189 210 10.1146/annurev-neuro-072116-031153 28772101
Goedert M, Eisenberg DS, Crowther RA. Propagation of tau aggregates and neurodegeneration. Annu Rev Neurosci. 2017;40(1):189–210.28772101 10.1146/annurev-neuro-072116-031153
136. Boi L Pisanu A Palmas MF Fusco G Carboni E Casu MA Modeling parkinson’s disease neuropathology and symptoms by intranigral inoculation of preformed human α-synuclein oligomers Int J Mol Sci 2020 10.3390/ijms21228535 33198335
Boi L, Pisanu A, Palmas MF, Fusco G, Carboni E, Casu MA, et al. Modeling parkinson’s disease neuropathology and symptoms by intranigral inoculation of preformed human α-synuclein oligomers. Int J Mol Sci. 2020. 10.3390/ijms21228535.33198335 10.3390/ijms21228535
137. Reiss AB Arain HA Stecker MM Siegart NM Kasselman LJ Amyloid toxicity in Alzheimer’s disease IJMS 2018 29 6 613 27
Reiss AB, Arain HA, Stecker MM, Siegart NM, Kasselman LJ. Amyloid toxicity in Alzheimer’s disease. IJMS. 2018;29(6):613–27.
138. Dehay B Bové J Rodríguez-Muela N Perier C Recasens A Boya P Pathogenic lysosomal depletion in Parkinson’s disease J Neurosci 2010 30 37 12535 12544 10.1523/JNEUROSCI.1920-10.2010 20844148
Dehay B, Bové J, Rodríguez-Muela N, Perier C, Recasens A, Boya P, et al. Pathogenic lysosomal depletion in Parkinson’s disease. J Neurosci. 2010;30(37):12535–44.20844148 10.1523/JNEUROSCI.1920-10.2010
139. McBrayer M Nixon RA Lysosome and calcium dysregulation in Alzheimer’s disease: partners in crime Biochem Soc Trans 2013 41 6 1495 1502 10.1042/BST20130201 24256243
McBrayer M, Nixon RA. Lysosome and calcium dysregulation in Alzheimer’s disease: partners in crime. Biochem Soc Trans. 2013;41(6):1495–502.24256243 10.1042/BST20130201
140. Ferrari V Cristofani R Cicardi ME Tedesco B Crippa V Chierichetti M Pathogenic variants of valosin-containing protein induce lysosomal damage and transcriptional activation of autophagy regulators in neuronal cells Neuropathol Appl Neurobiol 2022 48 5 1 22 10.1111/nan.12818
Ferrari V, Cristofani R, Cicardi ME, Tedesco B, Crippa V, Chierichetti M, et al. Pathogenic variants of valosin-containing protein induce lysosomal damage and transcriptional activation of autophagy regulators in neuronal cells. Neuropathol Appl Neurobiol. 2022;48(5):1–22.10.1111/nan.12818
141. Stagi M Klein ZA Gould TJ Bewersdorf J Strittmatter SM Lysosome size, motility and stress response regulated by fronto-temporal dementia modifier TMEM106B Mol Cell Neurosci 2014 61 226 240 10.1016/j.mcn.2014.07.006 25066864
Stagi M, Klein ZA, Gould TJ, Bewersdorf J, Strittmatter SM. Lysosome size, motility and stress response regulated by fronto-temporal dementia modifier TMEM106B. Mol Cell Neurosci. 2014;61:226–40.25066864 10.1016/j.mcn.2014.07.006
142. Dehay B Martinez-Vicente M Ramirez A Perier C Klein C Vila M Lysosomal dysfunction in Parkinson disease Autophagy 2012 8 9 1389 1391 10.4161/auto.21011 22885599
Dehay B, Martinez-Vicente M, Ramirez A, Perier C, Klein C, Vila M, et al. Lysosomal dysfunction in Parkinson disease. Autophagy. 2012;8(9):1389–91.22885599 10.4161/auto.21011
143. Bhattacharya J Edwards J Mamelak AN Schuman EM Long-range temporal correlations in the spontaneous spiking of neurons in the hippocampal-amygdala complex of humans Neuroscience 2005 131 2 547 555 10.1016/j.neuroscience.2004.11.013 15708495
Bhattacharya J, Edwards J, Mamelak AN, Schuman EM. Long-range temporal correlations in the spontaneous spiking of neurons in the hippocampal-amygdala complex of humans. Neuroscience. 2005;131(2):547–55.15708495 10.1016/j.neuroscience.2004.11.013
144. Fecto F Yan J Vemula SP Liu E Yang Y Chen W SQSTM1 mutations in familial and sporadic amyotrophic lateral sclerosis Arch Neurol 2011 68 11 1440 1446 10.1001/archneurol.2011.250 22084127
Fecto F, Yan J, Vemula SP, Liu E, Yang Y, Chen W, et al. SQSTM1 mutations in familial and sporadic amyotrophic lateral sclerosis. Arch Neurol. 2011;68(11):1440–6.22084127 10.1001/archneurol.2011.250
145. Maruyama H Morino H Ito H Izumi Y Kato H Watanabe Y Mutations of optineurin in amyotrophic lateral sclerosis Nature 2010 465 7295 223 226 10.1038/nature08971 20428114
Maruyama H, Morino H, Ito H, Izumi Y, Kato H, Watanabe Y, et al. Mutations of optineurin in amyotrophic lateral sclerosis. Nature. 2010;465(7295):223–6.20428114 10.1038/nature08971
146. Johnson JO Mandrioli J Benatar M Abramzon Y Van Deerlin VM Trojanowski JQ Exome sequencing reveals VCP mutations as a cause of familial ALS Neuron 2010 68 5 857 864 10.1016/j.neuron.2010.11.036 21145000
Johnson JO, Mandrioli J, Benatar M, Abramzon Y, Van Deerlin VM, Trojanowski JQ, et al. Exome sequencing reveals VCP mutations as a cause of familial ALS. Neuron. 2010;68(5):857–64.21145000 10.1016/j.neuron.2010.11.036
147. Freeman D Cedillos R Choyke S Lukic Z McGuire K Marvin S Alpha-synuclein induces lysosomal rupture and cathepsin dependent reactive oxygen species following endocytosis PLoS One 2013 8 4 e62143 10.1371/journal.pone.0062143 23634225
Freeman D, Cedillos R, Choyke S, Lukic Z, McGuire K, Marvin S, et al. Alpha-synuclein induces lysosomal rupture and cathepsin dependent reactive oxygen species following endocytosis. PLoS One. 2013;8(4):e62143.23634225 10.1371/journal.pone.0062143
148. Oku Y Murakami K Irie K Hoseki J Sakai Y Synthesized Aβ42 caused intracellular oxidative damage, leading to cell death, via lysosome rupture Cell Struct Funct 2017 42 1 71 79 10.1247/csf.17006 28413178
Oku Y, Murakami K, Irie K, Hoseki J, Sakai Y. Synthesized Aβ42 caused intracellular oxidative damage, leading to cell death, via lysosome rupture. Cell Struct Funct. 2017;42(1):71–9.28413178 10.1247/csf.17006
149. Zeineddine R Pundavela JF Corcoran L Stewart EM Do-Ha D Bax M SOD1 protein aggregates stimulate macropinocytosis in neurons to facilitate their propagation Mol Neurodegener 2015 10 1 57 10.1186/s13024-015-0053-4 26520394
Zeineddine R, Pundavela JF, Corcoran L, Stewart EM, Do-Ha D, Bax M, et al. SOD1 protein aggregates stimulate macropinocytosis in neurons to facilitate their propagation. Mol Neurodegener. 2015;10(1):57.26520394 10.1186/s13024-015-0053-4
150. Tysnes OB Storstein A Epidemiology of Parkinson’s disease J Neural Transm 2017 124 8 901 905 10.1007/s00702-017-1686-y 28150045
Tysnes OB, Storstein A. Epidemiology of Parkinson’s disease. J Neural Transm. 2017;124(8):901–5.28150045 10.1007/s00702-017-1686-y
151. Braak H Del Tredici K Neuropathological staging of brain pathology in sporadic Parkinson’s disease: separating the wheat from the chaff J Parkinsons Dis 2017 7 S71 85 10.3233/JPD-179001 28282810
Braak H, Del Tredici K. Neuropathological staging of brain pathology in sporadic Parkinson’s disease: separating the wheat from the chaff. J Parkinsons Dis. 2017;7:S71-85.28282810 10.3233/JPD-179001
152. Wu HC Chang KH Chiang MC Chen CM Alterations of plasma galectin-3 and C3 levels in patients with parkinson’s disease Brain Sci 2021 10.3390/brainsci11111515 35053760
Wu HC, Chang KH, Chiang MC, Chen CM. Alterations of plasma galectin-3 and C3 levels in patients with parkinson’s disease. Brain Sci. 2021. 10.3390/brainsci11111515.35053760 10.3390/brainsci11111515
153. García-Revilla J Boza-Serrano A Jin Y Vadukul DM Soldán-Hidalgo J Camprubí-Ferrer L Galectin-3 shapes toxic alpha-synuclein strains in Parkinson’s disease Acta Neuropathol 2023 10.1016/j.ibneur.2023.08.786 37202527
García-Revilla J, Boza-Serrano A, Jin Y, Vadukul DM, Soldán-Hidalgo J, Camprubí-Ferrer L, et al. Galectin-3 shapes toxic alpha-synuclein strains in Parkinson’s disease. Acta Neuropathol. 2023. 10.1016/j.ibneur.2023.08.786.37202527 10.1016/j.ibneur.2023.08.786
154. Boza-Serrano A Reyes JF Rey NL Leffler H Bousset L Nilsson U The role of Galectin-3 in α-synuclein-induced microglial activation Acta Neuropathol Commun 2014 2 1 156 25387690
Boza-Serrano A, Reyes JF, Rey NL, Leffler H, Bousset L, Nilsson U, et al. The role of Galectin-3 in α-synuclein-induced microglial activation. Acta Neuropathol Commun. 2014;2(1):156.25387690
155. Day JO Mullin S The genetics of parkinson’s disease and implications for clinical practice Genes 2021 10.3390/genes12071006 34208795
Day JO, Mullin S. The genetics of parkinson’s disease and implications for clinical practice. Genes. 2021. 10.3390/genes12071006.34208795 10.3390/genes12071006
156. Bandres-Ciga S Diez-Fairen M Kim JJ Singleton AB Genetics of Parkinson’s disease: an introspection of its journey towards precision medicine Neurobiol Dis 2020 137 104782 10.1016/j.nbd.2020.104782 31991247
Bandres-Ciga S, Diez-Fairen M, Kim JJ, Singleton AB. Genetics of Parkinson’s disease: an introspection of its journey towards precision medicine. Neurobiol Dis. 2020;137: 104782.31991247 10.1016/j.nbd.2020.104782
157. Chang D Nalls MA Hallgrímsdóttir IB Hunkapiller J van der Brug M Cai F A meta-analysis of genome-wide association studies identifies 17 new Parkinson’s disease risk loci Nat Genet 2017 49 10 1511 1516 10.1038/ng.3955 28892059
Chang D, Nalls MA, Hallgrímsdóttir IB, Hunkapiller J, van der Brug M, Cai F, et al. A meta-analysis of genome-wide association studies identifies 17 new Parkinson’s disease risk loci. Nat Genet. 2017;49(10):1511–6.28892059 10.1038/ng.3955
158. Nalls MA Blauwendraat C Vallerga CL Heilbron K Bandres-Ciga S Chang D Identification of novel risk loci, causal insights, and heritable risk for Parkinson’s disease: a meta-analysis of genome-wide association studies Lancet Neurol 2019 18 12 1091 1102 10.1016/S1474-4422(19)30320-5 31701892
Nalls MA, Blauwendraat C, Vallerga CL, Heilbron K, Bandres-Ciga S, Chang D, et al. Identification of novel risk loci, causal insights, and heritable risk for Parkinson’s disease: a meta-analysis of genome-wide association studies. Lancet Neurol. 2019;18(12):1091–102.31701892 10.1016/S1474-4422(19)30320-5
159. Zunke F The function of lysosomes and their role in Parkinson’s disease Neuroforum 2020 26 1 43 51 10.1515/nf-2019-0035
Zunke F. The function of lysosomes and their role in Parkinson’s disease. Neuroforum. 2020;26(1):43–51.10.1515/nf-2019-0035
160. Wallings R Connor-Robson N Wade-Martins R LRRK2 interacts with the vacuolar-type H+-ATPase pump a1 subunit to regulate lysosomal function Hum Mol Genet 2019 28 16 2696 2710 10.1093/hmg/ddz088 31039583
Wallings R, Connor-Robson N, Wade-Martins R. LRRK2 interacts with the vacuolar-type H+-ATPase pump a1 subunit to regulate lysosomal function. Hum Mol Genet. 2019;28(16):2696–710.31039583 10.1093/hmg/ddz088
161. Komori T Kuwahara T Fujimoto T Sakurai M Koyama-Honda I Fukuda M Phosphorylation of Rab29 at Ser185 regulates its localization and role in the lysosomal stress response in concert with LRRK2 J Cell Sci 2023 136 14 jcs261003 10.1242/jcs.261003 37365944
Komori T, Kuwahara T, Fujimoto T, Sakurai M, Koyama-Honda I, Fukuda M, et al. Phosphorylation of Rab29 at Ser185 regulates its localization and role in the lysosomal stress response in concert with LRRK2. J Cell Sci. 2023;136(14):jcs261003.37365944 10.1242/jcs.261003
162. van Veen S Martin S Van den Haute C Benoy V Lyons J Vanhoutte R ATP13A2 deficiency disrupts lysosomal polyamine export Nature 2020 578 7795 419 424 10.1038/s41586-020-1968-7 31996848
van Veen S, Martin S, Van den Haute C, Benoy V, Lyons J, Vanhoutte R, et al. ATP13A2 deficiency disrupts lysosomal polyamine export. Nature. 2020;578(7795):419–24.31996848 10.1038/s41586-020-1968-7
163. Yun SP Kim D Kim S Kim S Karuppagounder SS Kwon S-H α-Synuclein accumulation and GBA deficiency due to L444P GBA mutation contributes to MPTP-induced parkinsonism Mol Neurodegener 2018 13 1 1 10.1186/s13024-017-0233-5 29310663
Yun SP, Kim D, Kim S, Kim S, Karuppagounder SS, Kwon S-H, et al. α-Synuclein accumulation and GBA deficiency due to L444P GBA mutation contributes to MPTP-induced parkinsonism. Mol Neurodegener. 2018;13(1):1.29310663 10.1186/s13024-017-0233-5
164. Hu M Li P Wang C Feng X Geng Q Chen W Parkinson’s disease-risk protein TMEM175 is a proton-activated proton channel in lysosomes Cell 2022 185 13 2292 2308.e20 10.1016/j.cell.2022.05.021 35750034
Hu M, Li P, Wang C, Feng X, Geng Q, Chen W, et al. Parkinson’s disease-risk protein TMEM175 is a proton-activated proton channel in lysosomes. Cell. 2022;185(13):2292-2308.e20.35750034 10.1016/j.cell.2022.05.021
165. Usenko TS Bezrukova AI Bogdanova DA Kopytova AE Senkevich KA Gracheva EV Genetics variants and expression of the SCARB2 gene in the pathogenesis of Parkinson’s disease in Russia Neurosci Lett 2021 741 135509 10.1016/j.neulet.2020.135509 33227372
Usenko TS, Bezrukova AI, Bogdanova DA, Kopytova AE, Senkevich KA, Gracheva EV, et al. Genetics variants and expression of the SCARB2 gene in the pathogenesis of Parkinson’s disease in Russia. Neurosci Lett. 2021;741: 135509.33227372 10.1016/j.neulet.2020.135509
166. Rothaug M Zunke F Mazzulli JR Schweizer M Altmeppen H Lüllmann-Rauch R LIMP-2 expression is critical for β-glucocerebrosidase activity and α-synuclein clearance Proc Natl Acad Sci 2014 111 43 15573 15578 10.1073/pnas.1405700111 25316793
Rothaug M, Zunke F, Mazzulli JR, Schweizer M, Altmeppen H, Lüllmann-Rauch R, et al. LIMP-2 expression is critical for β-glucocerebrosidase activity and α-synuclein clearance. Proc Natl Acad Sci. 2014;111(43):15573–8.25316793 10.1073/pnas.1405700111
167. Reczek D Schwake M Schröder J Hughes H Blanz J Jin X LIMP-2 is a receptor for lysosomal mannose-6-phosphate-independent targeting of β-glucocerebrosidase Cell 2007 131 4 770 783 10.1016/j.cell.2007.10.018 18022370
Reczek D, Schwake M, Schröder J, Hughes H, Blanz J, Jin X, et al. LIMP-2 is a receptor for lysosomal mannose-6-phosphate-independent targeting of β-glucocerebrosidase. Cell. 2007;131(4):770–83.18022370 10.1016/j.cell.2007.10.018
168. Cuervo AM Stefanis L Fredenburg R Lansbury PT Sulzer D Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy Science 2004 305 5688 1292 1295 10.1126/science.1101738 15333840
Cuervo AM, Stefanis L, Fredenburg R, Lansbury PT, Sulzer D. Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. Science. 2004;305(5688):1292–5.15333840 10.1126/science.1101738
169. Taguchi YV Liu J Ruan J Pacheco J Zhang X Abbasi J Glucosylsphingosine promotes α-synuclein pathology in mutant GBA-associated parkinson’s disease J Neurosci 2017 37 40 9617LP 9631 10.1523/JNEUROSCI.1525-17.2017 28847804
Taguchi YV, Liu J, Ruan J, Pacheco J, Zhang X, Abbasi J, et al. Glucosylsphingosine promotes α-synuclein pathology in mutant GBA-associated parkinson’s disease. J Neurosci. 2017;37(40):9617LP – 9631.28847804 10.1523/JNEUROSCI.1525-17.2017
170. Suzuki M Fujikake N Takeuchi T Kohyama-Koganeya A Nakajima K Hirabayashi Y Glucocerebrosidase deficiency accelerates the accumulation of proteinase K-resistant α-synuclein and aggravates neurodegeneration in a Drosophila model of Parkinson’s disease Hum Mol Genet 2015 24 23 6675 6686 10.1093/hmg/ddv372 26362253
Suzuki M, Fujikake N, Takeuchi T, Kohyama-Koganeya A, Nakajima K, Hirabayashi Y, et al. Glucocerebrosidase deficiency accelerates the accumulation of proteinase K-resistant α-synuclein and aggravates neurodegeneration in a Drosophila model of Parkinson’s disease. Hum Mol Genet. 2015;24(23):6675–86.26362253 10.1093/hmg/ddv372
171. Zunke F Moise AC Belur NR Gelyana E Stojkovska I Dzaferbegovic H Reversible conformational conversion of α-synuclein into toxic assemblies by glucosylceramide Neuron 2018 97 1 92 107.e10 10.1016/j.neuron.2017.12.012 29290548
Zunke F, Moise AC, Belur NR, Gelyana E, Stojkovska I, Dzaferbegovic H, et al. Reversible conformational conversion of α-synuclein into toxic assemblies by glucosylceramide. Neuron. 2018;97(1):92-107.e10.29290548 10.1016/j.neuron.2017.12.012
172. Mazzulli JR Zunke F Isacson O Studer L Krainc D α-synuclein–induced lysosomal dysfunction occurs through disruptions in protein trafficking in human midbrain synucleinopathy models Proc Natl Acad Sci 2016 113 7 1931 1936 10.1073/pnas.1520335113 26839413
Mazzulli JR, Zunke F, Isacson O, Studer L, Krainc D. α-synuclein–induced lysosomal dysfunction occurs through disruptions in protein trafficking in human midbrain synucleinopathy models. Proc Natl Acad Sci. 2016;113(7):1931–6.26839413 10.1073/pnas.1520335113
173. Burrell JR Halliday GM Kril JJ Ittner LM Götz J Kiernan MC The frontotemporal dementia-motor neuron disease continuum Lancet 2016 388 10047 919 931 10.1016/S0140-6736(16)00737-6 26987909
Burrell JR, Halliday GM, Kril JJ, Ittner LM, Götz J, Kiernan MC, et al. The frontotemporal dementia-motor neuron disease continuum. Lancet. 2016;388(10047):919–31.26987909 10.1016/S0140-6736(16)00737-6
174. Younes K Miller BL Frontotemporal dementia: neuropathology, genetics, neuroimaging, and treatments Psychiatr Clin North Am 2020 43 2 331 344 10.1016/j.psc.2020.02.006 32439025
Younes K, Miller BL. Frontotemporal dementia: neuropathology, genetics, neuroimaging, and treatments. Psychiatr Clin North Am. 2020;43(2):331–44.32439025 10.1016/j.psc.2020.02.006
175. Masrori P Van Damme P Amyotrophic lateral sclerosis: a clinical review Eur J Neurol 2020 27 10 1918 1929 10.1111/ene.14393 32526057
Masrori P, Van Damme P. Amyotrophic lateral sclerosis: a clinical review. Eur J Neurol. 2020;27(10):1918–29.32526057 10.1111/ene.14393
176. Mandrioli J Mediani L Alberti S Carra S ALS and FTD: where RNA metabolism meets protein quality control Semin Cell Dev Biol 2020 99 183 192 10.1016/j.semcdb.2019.06.003 31254610
Mandrioli J, Mediani L, Alberti S, Carra S. ALS and FTD: where RNA metabolism meets protein quality control. Semin Cell Dev Biol. 2020;99:183–92.31254610 10.1016/j.semcdb.2019.06.003
177. Parobkova E Matej R Amyotrophic lateral sclerosis and frontotemporal lobar degenerations: similarities in genetic background Diagnostics 2021 11 3 1 21 10.3390/diagnostics11030509
Parobkova E, Matej R. Amyotrophic lateral sclerosis and frontotemporal lobar degenerations: similarities in genetic background. Diagnostics. 2021;11(3):1–21.10.3390/diagnostics11030509
178. Zhou JY Afjehi-Sadat L Asress S Duong DM Cudkowicz M Glass JD Galectin-3 is a candidate biomarker for amyotrophic lateral sclerosis: discovery by a proteomics approach J Proteom Res 2010 9 10 5133 5141 10.1021/pr100409r
Zhou JY, Afjehi-Sadat L, Asress S, Duong DM, Cudkowicz M, Glass JD, et al. Galectin-3 is a candidate biomarker for amyotrophic lateral sclerosis: discovery by a proteomics approach. J Proteom Res. 2010;9(10):5133–41.10.1021/pr100409r
179. Borrego-Écija S Pérez-Millan A Antonell A Fort-Aznar L Kaya-Tilki E León-Halcón A Galectin-3 is upregulated in frontotemporal dementia patients with subtype specificity Alzheimer Dement 2023 20 3 1515 26 10.1002/alz.13536
Borrego-Écija S, Pérez-Millan A, Antonell A, Fort-Aznar L, Kaya-Tilki E, León-Halcón A, et al. Galectin-3 is upregulated in frontotemporal dementia patients with subtype specificity. Alzheimer Dement. 2023;20(3):1515–26.10.1002/alz.13536
180. Zampatti S Peconi C Campopiano R Gambardella S Caltagirone C Giardina E C9orf72-related neurodegenerative diseases: from clinical diagnosis to therapeutic strategies Front Aging Neurosci 2022 14 June 1 9
Zampatti S, Peconi C, Campopiano R, Gambardella S, Caltagirone C, Giardina E. C9orf72-related neurodegenerative diseases: from clinical diagnosis to therapeutic strategies. Front Aging Neurosci. 2022;14(June):1–9.
181. Webster CP Smith EF Bauer CS Moller A Hautbergue GM Ferraiuolo L The C9orf72 protein interacts with Rab1a and the ULK1 complex to regulate initiation of autophagy EMBO J 2016 35 15 1656 1676 10.15252/embj.201694401 27334615
Webster CP, Smith EF, Bauer CS, Moller A, Hautbergue GM, Ferraiuolo L, et al. The C9orf72 protein interacts with Rab1a and the ULK1 complex to regulate initiation of autophagy. EMBO J. 2016;35(15):1656–76.27334615 10.15252/embj.201694401
182. Cozzi M Ferrari V Autophagy dysfunction in ALS: from transport to protein degradation J Mol Neurosci 2022 72 7 1456 1481 10.1007/s12031-022-02029-3 35708843
Cozzi M, Ferrari V. Autophagy dysfunction in ALS: from transport to protein degradation. J Mol Neurosci. 2022;72(7):1456–81.35708843 10.1007/s12031-022-02029-3
183. Cunningham KM Maulding K Ruan K Senturk M Grima JC Sung H TFEB/Mitf links impaired nuclear import to autophagolysosomal dysfunction in C9-ALS Elife 2020 9 e59419 10.7554/eLife.59419 33300868
Cunningham KM, Maulding K, Ruan K, Senturk M, Grima JC, Sung H, et al. TFEB/Mitf links impaired nuclear import to autophagolysosomal dysfunction in C9-ALS. Elife. 2020;9:e59419.33300868 10.7554/eLife.59419
184. Hardy J Rogaeva E Motor neuron disease and frontotemporal dementia: sometimes related, sometimes not Exp Neurol 2014 262 75 83 10.1016/j.expneurol.2013.11.006 24246281
Hardy J, Rogaeva E. Motor neuron disease and frontotemporal dementia: sometimes related, sometimes not. Exp Neurol. 2014;262:75–83.24246281 10.1016/j.expneurol.2013.11.006
185. Wu JJ Cai A Greenslade JE Higgins NR Fan C Le NTT ALS/FTD mutations in UBQLN2 impede autophagy by reducing autophagosome acidification through loss of function Proc Natl Acad Sci 2020 117 26 15230 15241 10.1073/pnas.1917371117 32513711
Wu JJ, Cai A, Greenslade JE, Higgins NR, Fan C, Le NTT, et al. ALS/FTD mutations in UBQLN2 impede autophagy by reducing autophagosome acidification through loss of function. Proc Natl Acad Sci. 2020;117(26):15230–41.32513711 10.1073/pnas.1917371117
186. Borg R Herrera P Purkiss A Cacciottolo R Cauchi RJ Reduced levels of ALS gene DCTN1 induce motor defects in Drosophila Front Neurosci 2023 17 June 1 10
Borg R, Herrera P, Purkiss A, Cacciottolo R, Cauchi RJ. Reduced levels of ALS gene DCTN1 induce motor defects in Drosophila. Front Neurosci. 2023;17(June):1–10.
187. Harding O Evans CS Ye J Cheung J Maniatis T Holzbaur ELF ALS- and FTD-associated missense mutations in TBK1 differentially disrupt mitophagy Proc Natl Acad Sci 2021 118 24 e2025053118 10.1073/pnas.2025053118 34099552
Harding O, Evans CS, Ye J, Cheung J, Maniatis T, Holzbaur ELF. ALS- and FTD-associated missense mutations in TBK1 differentially disrupt mitophagy. Proc Natl Acad Sci. 2021;118(24): e2025053118.34099552 10.1073/pnas.2025053118
188. Dominguez J Yu JT Tan YJ Ng A De Guzman MF Natividad B Novel optineurin frameshift insertion in a family with frontotemporal dementia and parkinsonism without amyotrophic lateral sclerosis Front Neurol 2021 12 May 1 8
Dominguez J, Yu JT, Tan YJ, Ng A, De Guzman MF, Natividad B, et al. Novel optineurin frameshift insertion in a family with frontotemporal dementia and parkinsonism without amyotrophic lateral sclerosis. Front Neurol. 2021;12(May):1–8.
189. Scarian E Fiamingo G Diamanti L Palmieri I Gagliardi S Pansarasa O The role of VCP mutations in the spectrum of amyotrophic lateral sclerosis—frontotemporal dementia Front Neurol 2022 13 February 1 15
Scarian E, Fiamingo G, Diamanti L, Palmieri I, Gagliardi S, Pansarasa O. The role of VCP mutations in the spectrum of amyotrophic lateral sclerosis—frontotemporal dementia. Front Neurol. 2022;13(February):1–15.
190. Bauer CS Webster CP Shaw AC Kok JR Castelli LM Lin YH Loss of TMEM106B exacerbates C9ALS/FTD DPR pathology by disrupting autophagosome maturation Front Cell Neurosci 2022 16 December 1 18
Bauer CS, Webster CP, Shaw AC, Kok JR, Castelli LM, Lin YH, et al. Loss of TMEM106B exacerbates C9ALS/FTD DPR pathology by disrupting autophagosome maturation. Front Cell Neurosci. 2022;16(December):1–18.
191. Huang L Liu Z Yuan Y Shen L Jiang H Tang B Mutation analysis of MFSD8 in an amyotrophic lateral sclerosis cohort from mainland China Eur J Neurosci 2021 53 4 1197 1206 10.1111/ejn.15058 33226711
Huang L, Liu Z, Yuan Y, Shen L, Jiang H, Tang B, et al. Mutation analysis of MFSD8 in an amyotrophic lateral sclerosis cohort from mainland China. Eur J Neurosci. 2021;53(4):1197–206.33226711 10.1111/ejn.15058
192. Simon MJ Logan T DeVos SL Di Paolo G Lysosomal functions of progranulin and implications for treatment of frontotemporal dementia Trends Cell Biol 2023 33 4 324 339 10.1016/j.tcb.2022.09.006 36244875
Simon MJ, Logan T, DeVos SL, Di Paolo G. Lysosomal functions of progranulin and implications for treatment of frontotemporal dementia. Trends Cell Biol. 2023;33(4):324–39.36244875 10.1016/j.tcb.2022.09.006
193. Van Der Zee J Mariën P Crols R Van Mossevelde S Dillen L Perrone F Mutated CTSF in adult-onset neuronal ceroid lipofuscinosis and FTD Neurol Genet 2016 2 5 1 6
Van Der Zee J, Mariën P, Crols R, Van Mossevelde S, Dillen L, Perrone F, et al. Mutated CTSF in adult-onset neuronal ceroid lipofuscinosis and FTD. Neurol Genet. 2016;2(5):1–6.
194. Ormeño F Hormazabal J Moreno J Riquelme F Rios J Criollo A Chaperone mediated autophagy degrades TDP-43 protein and is affected by TDP-43 aggregation Front Mol Neurosci 2020 13 February 1 17 32116540
Ormeño F, Hormazabal J, Moreno J, Riquelme F, Rios J, Criollo A, et al. Chaperone mediated autophagy degrades TDP-43 protein and is affected by TDP-43 aggregation. Front Mol Neurosci. 2020;13(February):1–17.32116540
195. Leibiger C Deisel J Aufschnaiter A Ambros S Tereshchenko M Verheijen BM TDP-43 controls lysosomal pathways thereby determining its own clearance and cytotoxicity Hum Mol Genet 2018 27 9 1593 1607 10.1093/hmg/ddy066 29474575
Leibiger C, Deisel J, Aufschnaiter A, Ambros S, Tereshchenko M, Verheijen BM, et al. TDP-43 controls lysosomal pathways thereby determining its own clearance and cytotoxicity. Hum Mol Genet. 2018;27(9):1593–607.29474575 10.1093/hmg/ddy066
196. Xia Q Wang H Hao Z Fu C Hu Q Gao F TDP-43 loss of function increases TFEB activity and blocks autophagosome-lysosome fusion EMBO J 2016 35 2 121 142 10.15252/embj.201591998 26702100
Xia Q, Wang H, Hao Z, Fu C, Hu Q, Gao F, et al. TDP-43 loss of function increases TFEB activity and blocks autophagosome-lysosome fusion. EMBO J. 2016;35(2):121–42.26702100 10.15252/embj.201591998
197. Barbier P Zejneli O Martinho M Lasorsa A Belle V Smet-Nocca C Role of tau as a microtubule-associated protein: structural and functional aspects Front Aging Neurosci 2019 10(JUL) 1 14
Barbier P, Zejneli O, Martinho M, Lasorsa A, Belle V, Smet-Nocca C, et al. Role of tau as a microtubule-associated protein: structural and functional aspects. Front Aging Neurosci. 2019;10(JUL):1–14.
198. Balabanian L Lessard DV Swaminathan K Yaninska P Sébastien M Wang S Tau differentially regulates the transport of early endosomes and lysosomes Mol Biol Cell 2022 33 13 ar128 10.1091/mbc.E22-01-0018 36129768
Balabanian L, Lessard DV, Swaminathan K, Yaninska P, Sébastien M, Wang S, et al. Tau differentially regulates the transport of early endosomes and lysosomes. Mol Biol Cell. 2022;33(13):ar128.36129768 10.1091/mbc.E22-01-0018
199. Bodea L-G Eckert A Ittner LM Piguet O Götz J Tau physiology and pathomechanisms in frontotemporal lobar degeneration J Neurochem 2016 138 S1 71 94 10.1111/jnc.13600 27306859
Bodea L-G, Eckert A, Ittner LM, Piguet O, Götz J. Tau physiology and pathomechanisms in frontotemporal lobar degeneration. J Neurochem. 2016;138(S1):71–94.27306859 10.1111/jnc.13600
200. Feng Q Luo Y Zhang XN Yang XF Hong XY Sun DS MAPT/Tau accumulation represses autophagy flux by disrupting IST1-regulated ESCRT-III complex formation: a vicious cycle in Alzheimer neurodegeneration Autophagy 2020 16 4 641 658 10.1080/15548627.2019.1633862 31223056
Feng Q, Luo Y, Zhang XN, Yang XF, Hong XY, Sun DS, et al. MAPT/Tau accumulation represses autophagy flux by disrupting IST1-regulated ESCRT-III complex formation: a vicious cycle in Alzheimer neurodegeneration. Autophagy. 2020;16(4):641–58.31223056 10.1080/15548627.2019.1633862
201. Lim F Hernández F Lucas JJ Gómez-Ramos P Morán MA Ávila J FTDP-17 mutations in tau transgenic mice provoke lysosomal abnormalities and tau filaments in forebrain Mol Cell Neurosci 2001 18 6 702 714 10.1006/mcne.2001.1051 11749044
Lim F, Hernández F, Lucas JJ, Gómez-Ramos P, Morán MA, Ávila J. FTDP-17 mutations in tau transgenic mice provoke lysosomal abnormalities and tau filaments in forebrain. Mol Cell Neurosci. 2001;18(6):702–14.11749044 10.1006/mcne.2001.1051
202. Trnka F Hoffmann C Wang H Sansevrino R Rankovic B Rost BR Aberrant phase separation of FUS leads to lysosome sequestering and acidification Front Cell Dev Biol 2021 9 October 1 13
Trnka F, Hoffmann C, Wang H, Sansevrino R, Rankovic B, Rost BR, et al. Aberrant phase separation of FUS leads to lysosome sequestering and acidification. Front Cell Dev Biol. 2021;9(October):1–13.
203. Kim A Lalonde K Truesdell A Welter PG Brocardo PS Rosenstock TR New avenues for the treatment of huntington’s disease Int J Mol Sci 2021 22 16 1 50 10.3390/ijms22168363
Kim A, Lalonde K, Truesdell A, Welter PG, Brocardo PS, Rosenstock TR, et al. New avenues for the treatment of huntington’s disease. Int J Mol Sci. 2021;22(16):1–50.10.3390/ijms22168363
204. Siew JJ Chen HM Chen HY Chen HL Chen CM Soong BW Galectin-3 is required for the microglia-mediated brain inflammation in a model of Huntington’s disease Nat Commun 2019 10 1 1 18 10.1038/s41467-019-11441-0 30602773
Siew JJ, Chen HM, Chen HY, Chen HL, Chen CM, Soong BW, et al. Galectin-3 is required for the microglia-mediated brain inflammation in a model of Huntington’s disease. Nat Commun. 2019;10(1):1–18.30602773 10.1038/s41467-019-11441-0
205. Erie C Sacino M Houle L Lu ML Wei J Altered lysosomal positioning affects lysosomal functions in a cellular model of Huntington’s disease Eur J Neurosci 2015 42 3 1941 1951 10.1111/ejn.12957 25997742
Erie C, Sacino M, Houle L, Lu ML, Wei J. Altered lysosomal positioning affects lysosomal functions in a cellular model of Huntington’s disease. Eur J Neurosci. 2015;42(3):1941–51.25997742 10.1111/ejn.12957
206. Zhou Y Peskett TR Landles C Warner JB Sathasivam K Smith EJ Correlative light and electron microscopy suggests that mutant huntingtin dysregulates the endolysosomal pathway in presymptomatic Huntington’s disease Acta Neuropathol Commun 2021 9 1 70 10.1186/s40478-021-01172-z 33853668
Zhou Y, Peskett TR, Landles C, Warner JB, Sathasivam K, Smith EJ, et al. Correlative light and electron microscopy suggests that mutant huntingtin dysregulates the endolysosomal pathway in presymptomatic Huntington’s disease. Acta Neuropathol Commun. 2021;9(1):70.33853668 10.1186/s40478-021-01172-z
207. Trajkovic K Jeong H Krainc D Mutant huntingtin is secreted via a late endosomal/lysosomal unconventional secretory pathway J Neurosci 2017 37 37 9000 9012 10.1523/JNEUROSCI.0118-17.2017 28821645
Trajkovic K, Jeong H, Krainc D. Mutant huntingtin is secreted via a late endosomal/lysosomal unconventional secretory pathway. J Neurosci. 2017;37(37):9000–12.28821645 10.1523/JNEUROSCI.0118-17.2017
208. Miao J Ma H Yang Y Liao Y Lin C Zheng J Microglia in Alzheimer’s disease: pathogenesis, mechanisms, and therapeutic potentials Front Aging Neurosci 2023 15 June 1 35
Miao J, Ma H, Yang Y, Liao Y, Lin C, Zheng J, et al. Microglia in Alzheimer’s disease: pathogenesis, mechanisms, and therapeutic potentials. Front Aging Neurosci. 2023;15(June):1–35.
209. Sun YY Wang Z Huang HC Roles of ApoE4 on the pathogenesis in Alzheimer’s disease and the potential therapeutic approaches Cell Mol Neurobiol 2023 43 7 3115 3136 10.1007/s10571-023-01365-1 37227619
Sun YY, Wang Z, Huang HC. Roles of ApoE4 on the pathogenesis in Alzheimer’s disease and the potential therapeutic approaches. Cell Mol Neurobiol. 2023;43(7):3115–36.37227619 10.1007/s10571-023-01365-1
210. Boza-Serrano A Vrillon A Minta K Paulus A Camprubí-Ferrer L Garcia M Galectin-3 is elevated in CSF and is associated with Aβ deposits and tau aggregates in brain tissue in Alzheimer’s disease Acta Neuropathol 2022 144 5 843 859 10.1007/s00401-022-02469-6 35895141
Boza-Serrano A, Vrillon A, Minta K, Paulus A, Camprubí-Ferrer L, Garcia M, et al. Galectin-3 is elevated in CSF and is associated with Aβ deposits and tau aggregates in brain tissue in Alzheimer’s disease. Acta Neuropathol. 2022;144(5):843–59.35895141 10.1007/s00401-022-02469-6
211. Bretou M Sannerud R Escamilla-Ayala A Leroy T Vrancx C Van Acker ZP Accumulation of APP C-terminal fragments causes endolysosomal dysfunction through the dysregulation of late endosome to lysosome-ER contact sites Dev Cell 2024 59 12 1571 1592.e9 10.1016/j.devcel.2024.03.030 38626765
Bretou M, Sannerud R, Escamilla-Ayala A, Leroy T, Vrancx C, Van Acker ZP, et al. Accumulation of APP C-terminal fragments causes endolysosomal dysfunction through the dysregulation of late endosome to lysosome-ER contact sites. Dev Cell. 2024;59(12):1571-1592.e9.38626765 10.1016/j.devcel.2024.03.030
212. Coffey EE Beckel JM Laties AM Mitchell CH Lysosomal alkalization and dysfunction in human fibroblasts with the Alzheimer’s disease-linked presenilin 1 A246E mutation can be reversed with cAMP Neuroscience 2014 263 111 124 10.1016/j.neuroscience.2014.01.001 24418614
Coffey EE, Beckel JM, Laties AM, Mitchell CH. Lysosomal alkalization and dysfunction in human fibroblasts with the Alzheimer’s disease-linked presenilin 1 A246E mutation can be reversed with cAMP. Neuroscience. 2014;263:111–24.24418614 10.1016/j.neuroscience.2014.01.001
213. Nixon RA Autophagy, amyloidogenesis and Alzheimer disease J Cell Sci 2007 120 23 4081 4091 10.1242/jcs.019265 18032783
Nixon RA. Autophagy, amyloidogenesis and Alzheimer disease. J Cell Sci. 2007;120(23):4081–91.18032783 10.1242/jcs.019265
214. Nixon RA The role of autophagy in neurodegenerative disease Nat Med 2013 19 8 983 997 10.1038/nm.3232 23921753
Nixon RA. The role of autophagy in neurodegenerative disease. Nat Med. 2013;19(8):983–97.23921753 10.1038/nm.3232
215. Lee JH Yang DS Goulbourne CN Im E Stavrides P Pensalfini A Faulty autolysosome acidification in Alzheimer’s disease mouse models induces autophagic build-up of Aβ in neurons, yielding senile plaques Nat Neurosci 2022 25 6 688 701 10.1038/s41593-022-01084-8 35654956
Lee JH, Yang DS, Goulbourne CN, Im E, Stavrides P, Pensalfini A, et al. Faulty autolysosome acidification in Alzheimer’s disease mouse models induces autophagic build-up of Aβ in neurons, yielding senile plaques. Nat Neurosci. 2022;25(6):688–701.35654956 10.1038/s41593-022-01084-8
216. Chae CW Yoon JH Lim JR Park JY Cho JH Jung YH TRIM16-mediated lysophagy suppresses high-glucose-accumulated neuronal Aβ Autophagy 2023 19 10 2752 2768 10.1080/15548627.2023.2229659 37357416
Chae CW, Yoon JH, Lim JR, Park JY, Cho JH, Jung YH, et al. TRIM16-mediated lysophagy suppresses high-glucose-accumulated neuronal Aβ. Autophagy. 2023;19(10):2752–68.37357416 10.1080/15548627.2023.2229659
217. Chin MY Ang KH Davies J Alquezar C Garda VG Rooney B Phenotypic screening using high-content imaging to identify lysosomal pH modulators in a neuronal cell model ACS Chem Neurosci 2022 13 10 1505 1516 10.1021/acschemneuro.1c00804 35522480
Chin MY, Ang KH, Davies J, Alquezar C, Garda VG, Rooney B, et al. Phenotypic screening using high-content imaging to identify lysosomal pH modulators in a neuronal cell model. ACS Chem Neurosci. 2022;13(10):1505–16.35522480 10.1021/acschemneuro.1c00804
218. Zhang Z Yue P Lu T Wang Y Wei Y Wei X Role of lysosomes in physiological activities, diseases, and therapy J Hematol Oncol 2021 14 1 79 10.1186/s13045-021-01087-1 33990205
Zhang Z, Yue P, Lu T, Wang Y, Wei Y, Wei X. Role of lysosomes in physiological activities, diseases, and therapy. J Hematol Oncol. 2021;14(1):79.33990205 10.1186/s13045-021-01087-1
219. Rusmini P Cortese K Crippa V Cristofani R Cicardi ME Ferrari V Trehalose induces autophagy via lysosomal-mediated TFEB activation in models of motoneuron degeneration Autophagy 2019 15 4 631 651 10.1080/15548627.2018.1535292 30335591
Rusmini P, Cortese K, Crippa V, Cristofani R, Cicardi ME, Ferrari V, et al. Trehalose induces autophagy via lysosomal-mediated TFEB activation in models of motoneuron degeneration. Autophagy. 2019;15(4):631–51.30335591 10.1080/15548627.2018.1535292
220. Massenzio F Peña-Altamira E Petralla S Virgili M Zuccheri G Miti A Microglial overexpression of fALS-linked mutant SOD1 induces SOD1 processing impairment, activation and neurotoxicity and is counteracted by the autophagy inducer trehalose Biochim Biophys Acta Mol Basis Dis 2018 1864 12 3771 3785 10.1016/j.bbadis.2018.10.013 30315929
Massenzio F, Peña-Altamira E, Petralla S, Virgili M, Zuccheri G, Miti A, et al. Microglial overexpression of fALS-linked mutant SOD1 induces SOD1 processing impairment, activation and neurotoxicity and is counteracted by the autophagy inducer trehalose. Biochim Biophys Acta Mol Basis Dis. 2018;1864(12):3771–85.30315929 10.1016/j.bbadis.2018.10.013
221. Perucho J Gómez A Muñoz MP de Yébenes JG Mena MÁ Casarejos MJ Trehalose rescues glial cell dysfunction in striatal cultures from HD R6/1 mice at early postnatal development Mol Cell Neurosci 2016 74 128 145 10.1016/j.mcn.2016.05.002 27236019
Perucho J, Gómez A, Muñoz MP, de Yébenes JG, Mena MÁ, Casarejos MJ. Trehalose rescues glial cell dysfunction in striatal cultures from HD R6/1 mice at early postnatal development. Mol Cell Neurosci. 2016;74:128–45.27236019 10.1016/j.mcn.2016.05.002
222. Pupyshev AB Tikhonova MA Akopyan AA Tenditnik MV Dubrovina NI Korolenko TA Therapeutic activation of autophagy by combined treatment with rapamycin and trehalose in a mouse MPTP-induced model of Parkinson’s disease Pharmacol Biochem Behav 2019 177 1 11 10.1016/j.pbb.2018.12.005 30582934
Pupyshev AB, Tikhonova MA, Akopyan AA, Tenditnik MV, Dubrovina NI, Korolenko TA. Therapeutic activation of autophagy by combined treatment with rapamycin and trehalose in a mouse MPTP-induced model of Parkinson’s disease. Pharmacol Biochem Behav. 2019;177:1–11.30582934 10.1016/j.pbb.2018.12.005
223. Galbiati M Meroni M Boido M Cescon M Rusmini P Crippa V Bicalutamide and trehalose ameliorate spinal and bulbar muscular atrophy pathology in mice Neurotherapeutics 2023 20 2 524 545 10.1007/s13311-023-01343-x 36717478
Galbiati M, Meroni M, Boido M, Cescon M, Rusmini P, Crippa V, et al. Bicalutamide and trehalose ameliorate spinal and bulbar muscular atrophy pathology in mice. Neurotherapeutics. 2023;20(2):524–45.36717478 10.1007/s13311-023-01343-x
224. Farrer M Stone J Mata IF Lincoln S Kachergus J Hulihan M LRRK2 mutations in Parkinson disease Neurology 2005 65 5 738 740 10.1212/01.WNL.0000169023.51764.b0 16157908
Farrer M, Stone J, Mata IF, Lincoln S, Kachergus J, Hulihan M, et al. LRRK2 mutations in Parkinson disease. Neurology. 2005;65(5):738–40.16157908 10.1212/01.WNL.0000169023.51764.b0
225. Bonet-Ponce L Cookson MR LRRK2 recruitment, activity, and function in organelles FEBS J 2022 289 22 6871 6890 10.1111/febs.16099 34196120
Bonet-Ponce L, Cookson MR. LRRK2 recruitment, activity, and function in organelles. FEBS J. 2022;289(22):6871–90.34196120 10.1111/febs.16099
226. Djarmati A Hagenah J Reetz K Winkler S Behrens MI Pawlack H ATP13A2 variants in early-onset Parkinson’s disease patients and controls Mov Disord 2009 24 14 2104 2111 10.1002/mds.22728 19705361
Djarmati A, Hagenah J, Reetz K, Winkler S, Behrens MI, Pawlack H, et al. ATP13A2 variants in early-onset Parkinson’s disease patients and controls. Mov Disord. 2009;24(14):2104–11.19705361 10.1002/mds.22728
227. Greuel A Trezzi JP Glaab E Ruppert MC Maier F Jäger C GBA variants in Parkinson’s disease: clinical, metabolomic, and multimodal neuroimaging phenotypes Mov Disord 2020 35 12 2201 2210 10.1002/mds.28225 32853481
Greuel A, Trezzi JP, Glaab E, Ruppert MC, Maier F, Jäger C, et al. GBA variants in Parkinson’s disease: clinical, metabolomic, and multimodal neuroimaging phenotypes. Mov Disord. 2020;35(12):2201–10.32853481 10.1002/mds.28225
228. Palomba NP Fortunato G Pepe G Modugno N Pietracupa S Damiano I Common and rare variants in TMEM175 gene concur to the pathogenesis of parkinson’s disease in italian patients Mol Neurobiol 2023 60 4 2150 2173 10.1007/s12035-022-03203-9 36609826
Palomba NP, Fortunato G, Pepe G, Modugno N, Pietracupa S, Damiano I, et al. Common and rare variants in TMEM175 gene concur to the pathogenesis of parkinson’s disease in italian patients. Mol Neurobiol. 2023;60(4):2150–73.36609826 10.1007/s12035-022-03203-9
229. Le Ber I Camuzat A Guerreiro R Bouya-Ahmed K Bras J Nicolas G SQSTM1 mutations in french patients with frontotemporal dementia or frontotemporal dementia with amyotrophic lateral sclerosis JAMA Neurol 2013 70 11 1403 1410 24042580
Le Ber I, Camuzat A, Guerreiro R, Bouya-Ahmed K, Bras J, Nicolas G, et al. SQSTM1 mutations in french patients with frontotemporal dementia or frontotemporal dementia with amyotrophic lateral sclerosis. JAMA Neurol. 2013;70(11):1403–10.24042580
230. Deng H-X Chen W Hong S-T Boycott KM Gorrie GH Siddique N Mutations in UBQLN2 cause dominant X-linked juvenile and adult-onset alS and ALS/dementia Nature 2011 477 7363 211 215 10.1038/nature10353 21857683
Deng H-X, Chen W, Hong S-T, Boycott KM, Gorrie GH, Siddique N, et al. Mutations in UBQLN2 cause dominant X-linked juvenile and adult-onset alS and ALS/dementia. Nature. 2011;477(7363):211–5.21857683 10.1038/nature10353
231. Nguyen HP Van Broeckhoven C van der Zee J ALS genes in the genomic era and their implications for FTD Trend Genet 2018 34 6 404 423 10.1016/j.tig.2018.03.001
Nguyen HP, Van Broeckhoven C, van der Zee J. ALS genes in the genomic era and their implications for FTD. Trend Genet. 2018;34(6):404–23.10.1016/j.tig.2018.03.001
232. Münch C Rosenbohm A Sperfeld A-D Uttner I Reske S Krause BJ Heterozygous R1101K mutation of the DCTN1 gene in a family with ALS and FTD Ann Neurol 2005 58 5 777 780 10.1002/ana.20631 16240349
Münch C, Rosenbohm A, Sperfeld A-D, Uttner I, Reske S, Krause BJ, et al. Heterozygous R1101K mutation of the DCTN1 gene in a family with ALS and FTD. Ann Neurol. 2005;58(5):777–80.16240349 10.1002/ana.20631
233. Cirulli ET Lasseigne BN Petrovski S Sapp PC Dion PA Leblond CS Exome sequencing in amyotrophic lateral sclerosis identifies risk genes and pathways Science 2015 347 6229 1436 41 10.1126/science.aaa3650 25700176
Cirulli ET, Lasseigne BN, Petrovski S, Sapp PC, Dion PA, Leblond CS, et al. Exome sequencing in amyotrophic lateral sclerosis identifies risk genes and pathways. Science. 2015;347(6229):1436–41.25700176 10.1126/science.aaa3650
234. Gijselinck I Van Mossevelde S van der Zee J Sieben A Philtjens S Heeman B Loss of TBK1 is a frequent cause of frontotemporal dementia in a Belgian cohort Neurology 2015 85 24 2116 2125 10.1212/WNL.0000000000002220 26581300
Gijselinck I, Van Mossevelde S, van der Zee J, Sieben A, Philtjens S, Heeman B, et al. Loss of TBK1 is a frequent cause of frontotemporal dementia in a Belgian cohort. Neurology. 2015;85(24):2116–25.26581300 10.1212/WNL.0000000000002220
235. Wong TH Pottier C Hondius DC Meeter LHH van Rooij JGJ Melhem S Three VCP mutations in patients with frontotemporal dementia J Alzheimer Dis 2018 65 1139 1146 10.3233/JAD-180301
Wong TH, Pottier C, Hondius DC, Meeter LHH, van Rooij JGJ, Melhem S, et al. Three VCP mutations in patients with frontotemporal dementia. J Alzheimer Dis. 2018;65:1139–46.10.3233/JAD-180301
236. Jun MH Han JH Lee YK Jang DJ Kaang BK Lee JA TMEM106B, a frontotemporal lobar dementia (FTLD) modifier, associates with FTD-3-linked CHMP2B, a complex of ESCRT-III Mol Brain 2015 8 1 85 10.1186/s13041-015-0177-z 26651479
Jun MH, Han JH, Lee YK, Jang DJ, Kaang BK, Lee JA. TMEM106B, a frontotemporal lobar dementia (FTLD) modifier, associates with FTD-3-linked CHMP2B, a complex of ESCRT-III. Mol Brain. 2015;8(1):85.26651479 10.1186/s13041-015-0177-z
237. Geier EG Bourdenx M Storm NJ Cochran JN Sirkis DW Hwang J-H Rare variants in the neuronal ceroid lipofuscinosis gene MFSD8 are candidate risk factors for frontotemporal dementia Acta Neuropathol 2019 137 1 71 88 10.1007/s00401-018-1925-9 30382371
Geier EG, Bourdenx M, Storm NJ, Cochran JN, Sirkis DW, Hwang J-H, et al. Rare variants in the neuronal ceroid lipofuscinosis gene MFSD8 are candidate risk factors for frontotemporal dementia. Acta Neuropathol. 2019;137(1):71–88.30382371 10.1007/s00401-018-1925-9
238. Mackenzie IRA The neuropathology and clinical phenotype of FTD with progranulin mutations Acta Neuropathol 2007 114 1 49 54 10.1007/s00401-007-0223-8 17458552
Mackenzie IRA. The neuropathology and clinical phenotype of FTD with progranulin mutations. Acta Neuropathol. 2007;114(1):49–54.17458552 10.1007/s00401-007-0223-8
239. Kelleher RJ Shen J Presenilin-1 mutations and Alzheimer’s disease Proc Natl Acad Sci 2017 114 4 629 631 10.1073/pnas.1619574114 28082723
Kelleher RJ, Shen J. Presenilin-1 mutations and Alzheimer’s disease. Proc Natl Acad Sci. 2017;114(4):629–31.28082723 10.1073/pnas.1619574114
240. Beckers J Tharkeshwar AK Van Damme P C9orf72 ALS-FTD: recent evidence for dysregulation of the autophagy-lysosome pathway at multiple levels Autophagy 2021 17 11 3306 3322 10.1080/15548627.2021.1872189 33632058
Beckers J, Tharkeshwar AK, Van Damme P. C9orf72 ALS-FTD: recent evidence for dysregulation of the autophagy-lysosome pathway at multiple levels. Autophagy. 2021;17(11):3306–22.33632058 10.1080/15548627.2021.1872189
241. Yang J Zhang C Targeting the autophagy-lysosomal pathway in huntington disease: a pharmacological perspective Front Aging Neurosci 2023 15 1175598 10.3389/fnagi.2023.1175598 37304076
Yang J, Zhang C. Targeting the autophagy-lysosomal pathway in huntington disease: a pharmacological perspective. Front Aging Neurosci. 2023;15:1175598.37304076 10.3389/fnagi.2023.1175598
